CUMULATIVE SUPPLEMENT 8
AUG'99



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGMENT AND SERVICES

1999

S.O. Subscription

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

Cumulative Supplement 8

AUGUST 1999

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

CUMULATIVE SUPPLEMENT 8
AUGUST 1999

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 19th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 19th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 20th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
PENEDERM INC (PENEDERM)	BERTEK PHARMACEUTICALS (BERTEK PHARMS)

1.3 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.4 AVAILABILITY OF THE EDITION

The 19th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $78.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 19th annual edition of the 1998 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder/orange/19bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at
http://www.fda.gov/cder/orange/supplement/patents.pdf.

The current listing of the Orphan Product Designations and Approvals is available at
http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1998) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1998	MAR 1999	JUN 1999	SEP 1999
DRUG PRODUCTS LISTED	9923	9975	10009	
SINGLE SOURCE	2504 (25.2%)	2520 (25.3%)	2523 (25.2%)	
MULTISOURCE	7308 (73.6%)	7344 (73.6%)	7375 (73.7%)	
THERAPEUTICALLY EQUIVALENT	6934 (69.9%)	6969 (69.9%)	7012 (70.1%)	
NOT THERAPEUTICALLY EQUIVALENT	374 (3.8%)	375 (3.8%)	363 (3.6%)	
EXCEPTIONS[1]	111 (1.1%)	111 (1.1%)	111 (1.1%)	
NEW MOLECULAR ENTITIES APPROVED	10	3	5	
NUMBER OF APPLICANTS	563	570	568	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACETAMINOPHEN; BUTALBITAL; CAPPEINE

CAPSULE; ORAL

		FEMCET			
> DLT >	AB	MALLINCKRODT	325MG;50MG;40MG	N89102 001	
> DLT >				JUN 19, 1985	
> ADD >		@	325MG;50MG;40MG	N89102 001	
> ADD >				JUN 19, 1985	
> DLT >		**TRIAD**			
> DLT >	AB	MALLINCKRODT	325MG;50MG;40MG	N89023 001	
> DLT >				JUN 19, 1985	
> ADD >		@	325MG;50MG;40MG	N89023 001	
> ADD >				JUN 19, 1985	

TABLET; ORAL

> ADD >		**BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE**			
> ADD >	AB	WEST WARD	500MG;50MG;40MG	N40336 001	
> ADD >				AUG 18, 1999	

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

	ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODONE BITARTRATE			
	+ MIKART	712.8MG;60MG;32MG	N40316 001	
			APR 28, 1999	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

	ALLAY			
AA	NORTON HN	500MG;5MG	N89907 001	
			JAN 13, 1989	
AA	ZENITH GOLDLINE	500MG;5MG	N89907 001	
			JAN 13, 1989	
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	MALLINCKRODT	500MG;5MG	N88956 001	
			JUL 19, 1985	
	ZYDONE			
AA	MALLINCKRODT	500MG;5MG	N88956 001	
			JUL 19, 1985	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

	OXYCODONE AND ACETAMINOPHEN			
AA	DURAMED	500MG;5MG	N40289 001	
			MAR 16, 1999	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

	OXYCODONE AND ACETAMINOPHEN			
AA	AMIDE PHARM	325MG;5MG	N40203 001	
			MAR 15, 1999	
	PERCOCET			
	ENDO PARMS	325MG;2.5MG	N40330 001	
			JUN 25, 1999	
AA	ENDO PHARMS	325MG;5MG	N40330 002	
			JUN 25, 1999	
	+	325MG;2.5MG	N40330 001	
			JUN 25, 1999	
	+	500MG;7.5MG	N40341 001	
			JUL 26, 1999	
	+	650MG;10MG	N40341 002	
			JUL 26, 1999	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	PROPACET 100			
AB	TEVA	650MG;100MG	N70107 001	
			JUN 12, 1985	
	@	650MG;100MG	N70107 001	
			JUN 12, 1985	

ACITRETIN

CAPSULE; ORAL

	SORIATANE			
	HLR	10MG	N19821 001	
			OCT 28, 1996	
	+	25MG	N19821 002	
			OCT 28, 1996	
	ROCHE	10MG	N19821 001	
			OCT 28, 1996	
	+	25MG	N19821 002	
			OCT 28, 1996	

ACYCLOVIR

CAPSULE; ORAL

	ACYCLOVIR			
AB	STASON	200MG	N75090 001	
			JAN 26, 1999	

ACYCLOVIR

TABLET; ORAL
ACYCLOVIR
AB CARLSBAD 400MG N75382 001 APR 30, 1999
AB 800MG N75382 002 APR 30, 1999

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR
AP ABBOTT EQ 50MG BASE/ML N75114 001 JUL 26, 1999

ACYCLOVIR SODIUM
AP + AM PHARM PARTNERS EQ 50MG BASE/ML N74930 001 MAY 13, 1998
\+ EQ 50MG BASE/ML N74930 001 MAY 13, 1998
AP MERIDIAN MEDCL TECHN EQ 50MG BASE/ML N75065 001 FEB 25, 1999

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL
AB MEDEVA 0.09MG/INH N72273 001 AUG 14, 1996
AB MEDEVA PHARMS MA 0.09MG/INH N72273 001 AUG 14, 1996

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE
AN HI TECH PHARMA EQ 0.083% BASE N75063 001 FEB 09, 1999

SYRUP; ORAL
ALBUTEROL SULFATE
AA UDL EQ 2MG BASE/5ML N75262 001 MAR 30, 1999

ALITRETINOIN

GEL; TOPICAL
PANRETIN
\+ LIGAND EQ 0.1% BASE N20886 001 FEB 02, 1999

ALLOPURINOL

TABLET; ORAL
ZYLOPRIM
AB FARO PHARMS 100MG N16084 001
AB + 300MG N16084 002
AB GLAXO WELLCOME 100MG N16084 001
AB + 300MG N16084 002

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION
CERNEVIT-12
\+ BAXTER HLTHCARE 11.2 IU/VIAL;125MG/VIAL;60 UGM/VIAL; 200 IU/VIAL;5.5MG/VIAL;414 UGM/VIAL; 46MG/VIAL;17.25MG/VIAL;4.53MG/VIAL; 4.14MG/VIAL;3.51MG/VIAL; 3,500 IU/VIAL N20924 001 APR 06, 1999

ALPRAZOLAM

CONCENTRATE; ORAL
ALPRAZOLAM
ROXANE 1MG/ML N74312 001 OCT 31, 1993
\+ 1MG/ML N74312 001 OCT 31, 1993

SOLUTION; ORAL
ALPRAZOLAM
ROXANE 0.5MG/5ML N74314 001 OCT 31, 1993
\+ 0.5MG/5ML N74314 001 OCT 31, 1993

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

> ADD >	**AB**	ALPHAPHARM	**2MG**	**N74046 004**
> ADD				MAY 07, 1997

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL

AP	GENSIA SICOR PHARMS	**0.5MG/ML**	**N75196 001**
			APR 30, 1999

AMCINONIDE

CREAM; TOPICAL
CYCLOCORT

	@ FUJISAWA HLTHCARE	0.025%	N18116 001
	+	0.1%	N18116 002
	LEDERLE	0.025%	N18116 001
	+	0.1%	N18116 002

LOTION; TOPICAL
CYCLOCORT

	+ FUJISAWA HLTHCARE	0.1%	N19729 001
			JUN 13, 1988
	+ LEDERLE	0.1%	N19729 001
			JUN 13, 1988

OINTMENT; TOPICAL
CYCLOCORT

	+ FUJISAWA HLTHCARE	0.1%	N18498 001
	+ WYETH AYERST	0.1%	N18498 001

AMINO ACIDS

INJECTABLE; INJECTION
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

	FRESENIUS KABI	5.2%	N18901 001
			APR 06, 1984
	PHARMACIA AND UPJOHN	5.2%	N18901 001
			APR 06, 1984

NEOPHAM 6.4%

	@ FRESENIUS KABI	6.4%	N18792 001
			JAN 17, 1984

AMINO ACIDS

INJECTABLE; INJECTION
NEOPHAM 6.4%

	@ PHARMACIA AND UPJOHN	6.4%	N18792 001
			JAN 17, 1984

NOVAMINE 11.4%

	FRESENIUS KABI	11.4%	N17957 003
			AUG 09, 1982
	PHARMACIA AND UPJOHN	11.4%	N17957 003
			AUG 09, 1982

NOVAMINE 15%

	FRESENIUS KABI	15%	N17957 004
			NOV 28, 1986
	PHARMACIA AND UPJOHN	15%	N17957 004
			NOV 28, 1986

NOVAMINE 8.5%

	@ FRESENIUS KABI	8.5%	N17957 002
			AUG 09, 1982
	@ PHARMACIA AND UPJOHN	8.5%	N17957 002
			AUG 09, 1982

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION
VEINAMINE 8%

	@ FRESENIUS KABI	8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML	N17957 001
	@ PHARMACIA AND UPJOHN	8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML	N17957 001

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE

AP	SMITH AND NEPHEW	**25MG/ML**	**N88749 001**
			MAY 30, 1985
	@	25MG/ML	N88749 001
			MAY 30, 1985

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
AMIODARONE HCL

AB	ALPHAPHARM	**200MG**	**N75188 001**
			FEB 24, 1999

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

	AMIODARONE HCL			
AB	NOVOPHARM	**200MG**	**N74895 001**	APR 16, 1999

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION

	AMITRIPTYLINE HCL			
AP	STERIS	**10MG/ML**	**N85594 001**	
	@	10MG/ML	N85594 001	
	ELAVIL			
AP	* ZENECA	**10MG/ML**	**N12704 001**	
	+	10MG/ML	N12704 001	

TABLET; ORAL

	AMITRIPTYLINE HCL			
BP	COPLEY PHARM	**10MG**	**N88421 001**	APR 30, 1984
BP		**25MG**	**N88422 001**	APR 30, 1984
BP		**50MG**	**N88423 001**	APR 30, 1984
BP		**75MG**	**N88424 001**	APR 30, 1984
BP		**100MG**	**N88425 001**	APR 30, 1984
BP		**150MG**	**N88426 001**	APR 30, 1984
	@	10MG	N88421 001	APR 30, 1984
	@	25MG	N88422 001	APR 30, 1984
	@	50MG	N88423 001	APR 30, 1984
	@	75MG	N88424 001	APR 30, 1984
	@	100MG	N88425 001	APR 30, 1984
	@	150MG	N88426 001	APR 30, 1984
	ENDEP			
AB	ROCHE	**10MG**	**N83639 001**	
AB		**25MG**	**N83639 002**	
AB		**50MG**	**N83639 003**	
AB		**75MG**	**N83639 004**	

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	ENDEP			
AB	ROCHE	**100MG**	**N83639 005**	
	@	10MG	N83639 001	
	@	25MG	N83639 002	
	@	50MG	N83639 003	
	@	75MG	N83639 004	
	@	100MG	N83639 005	

AMOXICILLIN

CAPSULE; ORAL

	AMOXICILLIN			
AB	RANBAXY	**250MG**	**N65016 001**	APR 08, 1999
AB		**500MG**	**N65016 002**	APR 08, 1999

POWDER FOR RECONSTITUTION; ORAL

	AMOXIL			
	SMITHKLINE BEECHAM	200MG/5ML	N50760 001	APR 15, 1999
	+	400MG/5ML	N50760 002	APR 15, 1999

TABLET, CHEWABLE; ORAL

	AMOXIL			
	SMITHKLINE BEECHAM	200MG	N50761 001	APR 15, 1999
	+	400MG	N50761 002	APR 15, 1999

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

	AMPHOTEC			
	+ ALZA	50MG/VIAL	N50729 001	NOV 22, 1996
	+	100MG/VIAL	N50729 002	NOV 22, 1996
	+ SEQUUS	50MG/VIAL	N50729 001	NOV 22, 1996
	+	100MG/VIAL	N50729 002	NOV 22, 1996

AMPRENAVIR

CAPSULE; ORAL
AGENERASE
GLAXO WELLCOME 50MG N21007 001 APR 15, 1999
\+ 150MG N21007 002 APR 15, 1999

SOLUTION; ORAL
AGENERASE
\+ GLAXO WELLCOME 15MG/ML N21039 001 APR 15, 1999

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
KABIVITE PED F + W KIT
\+ FRESENIUS KABI N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A N20176 001 DEC 29, 1993
\+ PHARMACIA AND UPJOHN N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A N20176 001 DEC 29, 1993

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
AB ENDO PHARMS 325MG;50MG;40MG;30MG N75351 001 MAR 05, 1999

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE
AB STEVENS J 385MG;30MG;25MG N74988 001 APR 30, 1999
AB 770MG;60MG;50MG N74988 002 APR 30, 1999

ASTEMIZOLE

TABLET; ORAL
HISMANAL
\+ JANSSEN 10MG N19402 001 DEC 29, 1988

ATENOLOL

TABLET; ORAL
ATENOLOL
AB APOTHECON 50MG N73317 001 MAR 20, 1992
AB 100MG N73318 001 MAR 20, 1992
@ 50MG N73317 001 MAR 20, 1992
@ 100MG N73318 001 MAR 20, 1992

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL W/ ATROPINE SULFATE
AA ZENITH GOLDLINE 0.025MG;2.5MG N86727 001
@ 0.025MG;2.5MG N86727 001

AZATHIOPRINE

TABLET; ORAL
AZATHIOPRINE
AB APPLIED ANAL 50MG N75252 001 JUN 07, 1999

IMURAN
>ADD< AB \+ FARO PHARMS 50MG N16324 001
>DLT< AB \+ GLAXO WELLCOME 50MG N16324 001

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION
IMURAN

> ADD >	AP	+	FARO PHARMS	EQ 100MG BASE/VIAL	N17391 001
> DLT >	AP	+	GLAXO WELLCOME	EQ 100MG BASE/VIAL	N17391 001

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

AT	+	ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N60731 002
	@		400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N60731 002
AT		PHARMADERM	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62166 002
	+		400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62166 002

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL
CORZIDE

	APOTHECON	5MG;40MG	N18647 001 MAY 25, 1983
+		5MG;80MG	N18647 002 MAY 25, 1983
	BRISTOL MYERS SQUIBB	5MG;40MG	N18647 001 MAY 25, 1983
+		5MG;80MG	N18647 002 MAY 25, 1983

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
PRE-PEN

+	BAYER	60 UMOLAR	N50114 001
+	HOLLISTER STIER LABS	60 UMOLAR	N50114 001

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	ALTANA	EQ 0.05% BASE	N75373 001 JUN 22, 1999

BETAMETHASONE VALERATE

AEROSOL; TOPICAL
LUXIQ

+	CONNETICS	EQ 0.12% BASE	N20934 001 FEB 28, 1999

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN

+	GLAXO WELLCOME	50MG	N20358 001 OCT 04, 1996
+		100MG	N20358 002 OCT 04, 1996
+		150MG	N20358 003 OCT 04, 1996

WELLBUTRIN SR

+	GLAXO WELLCOME	50MG	N20358 001 OCT 04, 1996
+		100MG	N20358 002 OCT 04, 1996
+		150MG	N20358 003 OCT 04, 1996

BUSULFAN

INJECTABLE; INJECTION
BUSULFEX

+	ORPHAN MEDCL	6MG/ML	N20954 001 FEB 04, 1999

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT

+	SYNTEX	2%	N19215 001 NOV 25, 1985

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

	FEMSTAT			
	@ SYNTEX	2%	N19215 001	NOV 25, 1985
	FEMSTAT ONE			
+	KV PHARM	2%	N19881 001	FEB 07, 1997
+	SYNTEX	2%	N19881 001	FEB 07, 1997

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

	ENDOSOL EXTRA			
AT	AKORN	0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML	N20079 001	NOV 27, 1991
AT	ALLERGAN	0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML	N20079 001	NOV 27, 1991

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER			
	B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML	N18271 001	
	@	37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML	N18271 001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

	ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER			
	B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML	N18269 002	JAN 17, 1983
	@	35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML	N18269 002	JAN 17, 1983

CAPECITABINE

TABLET; ORAL

	XELODA			
	HLR	150MG	N20896 001	APR 30, 1998
	ROCHE	150MG	N20896 001	APR 30, 1998

CAPTOPRIL

TABLET; ORAL

	CAPTOPRIL			
AB	BAKER NORTON	12.5MG	N74590 004	AUG 30, 1996
AB		25MG	N74590 002	AUG 30, 1996
AB		50MG	N74590 001	AUG 30, 1996
AB		100MG	N74590 003	AUG 30, 1996
AB	ZENITH GOLDLINE	12.5MG	N74590 004	AUG 30, 1996
AB		25MG	N74590 002	AUG 30, 1996
AB		50MG	N74590 001	AUG 30, 1996
AB		100MG	N74590 003	AUG 30, 1996

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION
GEOPEN

+	ROERIG	EQ 1GM BASE/VIAL	N50306 001	
+		EQ 2GM BASE/VIAL	N50306 004	
+		EQ 5GM BASE/VIAL	N50306 002	
+		EQ 10GM BASE/VIAL	N50306 006	
+		EQ 30GM BASE/VIAL	N50306 007	
@		EQ 1GM BASE/VIAL	N50306 001	
@		EQ 2GM BASE/VIAL	N50306 004	
@		EQ 5GM BASE/VIAL	N50306 002	
@		EQ 10GM BASE/VIAL	N50306 006	
@		EQ 30GM BASE/VIAL	N50306 007	

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OCUPRESS

+	CIBA	1%	N19972 001	MAY 23, 1990
+	OTSUKA	1%	N19972 001	MAY 23, 1990

CEFACLOR

CAPSULE; ORAL
CEFACLOR

AB	LEDERLE	EQ 250MG BASE	N64107 001	APR 27, 1995
AB		EQ 500MG BASE	N64107 002	APR 27, 1995
@		EQ 250MG BASE	N64107 001	APR 27, 1995
@		EQ 500MG BASE	N64107 002	APR 27, 1995
AB	TEVA	EQ 250MG BASE	N64081 001	SEP 16, 1996
AB		EQ 500MG BASE	N64081 002	SEP 16, 1996
@		EQ 250MG BASE	N64081 001	SEP 16, 1996
@		EQ 500MG BASE	N64081 002	SEP 16, 1996

POWDER FOR RECONSTITUTION; ORAL
CEFACLOR

AB	LEDERLE	EQ 125MG BASE/5ML	N64114 001	APR 28, 1995

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL
CEFACLOR

AB	LEDERLE	EQ 187MG BASE/5ML	N64115 001	APR 28, 1995
AB		EQ 250MG BASE/5ML	N64116 001	APR 28, 1995
AB		EQ 375MG BASE/5ML	N64110 001	APR 28, 1995
@		EQ 125MG BASE/5ML	N64114 001	APR 28, 1995
@		EQ 187MG BASE/5ML	N64115 001	APR 28, 1995
@		EQ 250MG BASE/5ML	N64116 001	APR 28, 1995
@		EQ 375MG BASE/5ML	N64110 001	APR 28, 1995

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL

AB	BARR	EQ 500MG BASE	N65015 001	JUN 22, 1999

TABLET; ORAL
CEFADROXIL

AB	RANBAXY	EQ 1GM BASE	N65018 001	APR 23, 1999

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION
CEPTAZ

AP	+ GLAXO WELLCOME	1GM/VIAL	N50646 002	SEP 27, 1990
AP	+	2GM/VIAL	N50646 003	SEP 27, 1990
AP	+	10GM/VIAL	N50646 004	SEP 27, 1990
+		1GM/VIAL	N50646 002	SEP 27, 1990
+		2GM/VIAL	N50646 003	SEP 27, 1990
+		10GM/VIAL	N50646 004	SEP 27, 1990

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

		PENTACEF		
AP		SMITHKLINE BEECHAM	1GM/VIAL	N63322 001 NOV 07, 1995
AP			1GM/VIAL	N64006 001 MAR 31, 1992
AP			2GM/VIAL	N63322 002 NOV 07, 1995
AP			2GM/VIAL	N64006 002 MAR 31, 1992
AP			10GM/VIAL	N64008 002 MAR 31, 1992
			6GM/VIAL	N64008 001 MAR 31, 1992
	@		1GM/VIAL	N63322 001 NOV 07, 1995
	@		1GM/VIAL	N64006 001 MAR 31, 1992
	@		2GM/VIAL	N63322 002 NOV 07, 1995
	@		2GM/VIAL	N64006 002 MAR 31, 1992
	@		6GM/VIAL	N64008 001 MAR 31, 1992
	@		10GM/VIAL	N64008 002 MAR 31, 1992

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

		CEPHALOTHIN SODIUM		
> DLT >	AP	ABBOTT	EQ 1GM BASE/VIAL	N62547 001 SEP 11, 1985
> DLT >	AP		EQ 2GM BASE/VIAL	N62547 002 SEP 11, 1985
> ADD >	@		EQ 1GM BASE/VIAL	N62547 001 SEP 11, 1985
> ADD >	@		EQ 2GM BASE/VIAL	N62547 002 SEP 11, 1985

CERIVASTATIN SODIUM

TABLET; ORAL

		BAYCOL		
+		BAYER	0.3MG	N20740 004 JUN 26, 1997

CERIVASTATIN SODIUM

TABLET; ORAL

		BAYCOL		
		BAYER	0.3MG	N20740 004 JUN 26, 1997
+			0.4MG	N20740 005 MAY 24, 1999

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

		A-POXIDE		
	@	ABBOTT	5MG	N85517 001
	@		5MG	N85517 001

CHLOROTRIANISENE

CAPSULE; ORAL

		CHLOROTRIANISENE		
AA		BANNER PHARMACAPS	12MG	N84652 001
	@		12MG	N84652 001
		TACE		
AA	+	HOECHST MARION RSSL	12MG	N08102 004
	+		12MG	N08102 004

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

		CHLORPROMAZINE HCL		
AA		PHARM ASSOC	100MG/ML	N40224 001 JAN 26, 1999

CHOLESTYRAMINE

POWDER; ORAL

		CHOLESTYRAMINE		
AB		BAKER NORTON	EQ 4GM RESIN/PACKET	N74771 001 JUL 09, 1997
AB			EQ 4GM RESIN/SCOOPFUL	N74771 002 JUL 09, 1997
AB		ZENITH GOLDLINE	EQ 4GM RESIN/PACKET	N74771 001 JUL 09, 1997
AB			EQ 4GM RESIN/SCOOPFUL	N74771 002 JUL 09, 1997

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE LIGHT
AB COPLEY PHARM EQ 4GM RESIN/SCOOPFUL N74555 002 SEP 30, 1998

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC
CATARASE
\+ CIBA 300 UNITS/VIAL N16938 001
@ 300 UNITS/VIAL N16938 001
ZOLYSE
ALCON 750 UNITS/VIAL N11903 001
\+ 750 UNITS/VIAL N11903 001

CILOSTAZOL

TABLET; ORAL
PLETAL
OTSUKA 50MG N20863 001 JAN 15, 1999
\+ 100MG N20863 002 JAN 15, 1999

CISPLATIN

INJECTABLE; INJECTION
CISPLATIN
AP AM PHARM PARTNERS 1MG/ML N74735 001 JUL 16, 1999

PLATINOL-AQ
AP + BRISTOL MYERS 1MG/ML N18057 004 NOV 08, 1988
\+ 1MG/ML N18057 004 NOV 08, 1988

CLARITHROMYCIN

GRANULE, FOR RECONSTITUTION; ORAL
BIAXIN
> ADD > > ADD > ABBOTT 187MG/5ML N50698 003 SEP 30, 1998

> DLT > > ADD > > DLT > > ADD > > DLT > > DLT > > ADD > > ADD >

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLEOCIN HCL
AB + PHARMACIA AND UPJOHN EQ 75MG BASE N50162 001
AB EQ 75MG BASE N50162 001
AB + EQ 150MG BASE N50162 002
AB EQ 150MG BASE N50162 002
EQ 300MG BASE N50162 003 APR 14, 1988
\+ EQ 300MG BASE N50162 003 APR 14, 1988

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE
AP SOLOPAK EQ 150MG BASE/ML N62819 001 MAR 15, 1988
AP EQ 150MG BASE/ML N62852 001 MAR 17, 1988
@ EQ 150MG BASE/ML N62819 001 MAR 15, 1988
@ EQ 150MG BASE/ML N62852 001 MAR 17, 1988
AP STERIS EQ 150MG BASE/ML N62900 001 JUN 08, 1988
AP EQ 150MG BASE/ML N63079 001 MAR 05, 1990
@ EQ 150MG BASE/ML N62900 001 JUN 08, 1988
@ EQ 150MG BASE/ML N63079 001 MAR 05, 1990

> ADD > > ADD > > ADD > > ADD >

SUPPOSITORY; VAGINAL
CLEOCIN
\+ PHARMACIA AND UPJOHN 100MG N50767 001 AUG 13, 1999

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE
> ADD > > ADD > AB ALPHARMA US PHARM 0.05% N74139 001 AUG 03, 1994
> DLT > > DLT > AB NMC 0.05% N74139 001 AUG 03, 1994

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	ALTANA	0.05%	N75430 001 MAY 26, 1999
@		0.05%	N75430 001 MAY 26, 1999

GEL; TOPICAL
CLOBETASOL PROPIONATE

AB	TARO	0.05%	N75279 001 MAY 28, 1999

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE

AT	ALTANA	0.05%	N75391 001 FEB 08, 1999

CLOMIPHENE CITRATE

TABLET; ORAL
CLOMIPHENE CITRATE

> ADD >	AB	PAR PHARM	50MG	N75528 001 AUG 30, 1999
> ADD >				

CLOXACILLIN SODIUM

CAPSULE; ORAL
CLOXAPEN

AB		SMITHKLINE BEECHAM	EQ 250MG BASE	N62233 001
AB			EQ 500MG BASE	N62233 002
	@		EQ 250MG BASE	N62233 001
	@		EQ 500MG BASE	N62233 002

POWDER FOR RECONSTITUTION; ORAL
CLOXACILLIN SODIUM

AA		TEVA	EQ 125MG BASE/5ML	N62268 001
	+		EQ 125MG BASE/5ML	N62268 001
		TEGOPEN		
AA	+	APOTHECON	EQ 125MG BASE/5ML	N61453 001
	@		EQ 125MG BASE/5ML	N61453 001

CLOZAPINE

TABLET; ORAL
CLOZAPINE

AB		CREIGHTON	25MG	N74546 001 AUG 30, 1996
AB			100MG	N74546 002 AUG 30, 1996
AB		GENEVA PHARMS	25MG	N74546 001 AUG 30, 1996
AB			100MG	N74546 002 AUG 30, 1996
AB		MYLAN	25MG	N75417 001 MAY 27, 1999
AB			100MG	N75417 002 MAY 27, 1999

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLISTIMETHATE

AP	PHARMA TEK	EQ 150MG BASE/VIAL	N64216 001 FEB 26, 1999

COLY-MYCIN M

AP	+	PARKEDALE	EQ 150MG BASE/VIAL	N50108 002
	+		EQ 150MG BASE/VIAL	N50108 002

CORTICOTROPIN

INJECTABLE; INJECTION
CORTICOTROPIN

AP	+	STERIS	40 UNITS/VIAL	N88772 001 NOV 21, 1984
	@		40 UNITS/VIAL	N88772 001 NOV 21, 1984

CROMOLYN SODIUM

CAPSULE; ORAL
GASTROCROM

	+	MEDEVA	100MG	N19188 001 DEC 22, 1989
	@		100MG	N19188 001 DEC 22, 1989

CROMOLYN SODIUM

SOLUTION; INHALATION
CROMOLYN SODIUM

AN	ALPHARMA	10MG/ML	N75067 001	JUL 19, 1999

SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

AT	ALCON	4%	N75282 001	JUN 16, 1999

CROMOPTIC

AT	KING PHARMS	4%	N75088 001	APR 27, 1999

CYCLOPHOSPHAMIDE

TABLET; ORAL
CYCLOPHOSPHAMIDE

>ADD>	AB	ROXANE	25MG	N40032 001	AUG 17, 1999
>ADD>	AB		50MG	N40032 002	AUG 17, 1999

CYTOXAN

>ADD>	AB	BRISTOL MYERS SQUIBB	25MG	N12141 002	
>ADD>	AB	+	50MG	N12141 001	
>DLT>			25MG	N12141 002	
>DLT>		*	50MG	N12141 001	

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION
CYSTEINE HCL

@	FRESENIUS KABI	7.25%	N19523 001	OCT 22, 1986
@	PHARMACIA AND UPJOHN	7.25%	N19523 001	OCT 22, 1986

CYTARABINE

INJECTABLE, LIPOSOMAL; INJECTION
DEPOCYT

>DLT>		+ DEPOTECH	10MG/ML	N21041 001	APR 01, 1999
>ADD>		+ SKYEPHARMA	10MG/ML	N21041 001	APR 01, 1999

DACARBAZINE

INJECTABLE; INJECTION
DACARBAZINE

>ADD>	AP	AM PHARM PARTNERS	100MG/VIAL	N75371 001	AUG 27, 1999
>ADD>	AP		200MG/VIAL	N75371 002	AUG 27, 1999

DTIC-DOME

>ADD>	AP	+ BAYER	100MG/VIAL	N17575 001	
>DLT>		*	100MG/VIAL	N17575 001	

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
CERUBIDINE

AP	+ BEDFORD	EQ 20MG BASE/VIAL	N64103 001	FEB 03, 1995
	*	EQ 20MG BASE/VIAL	N64103 001	FEB 03, 1995

DAUNORUBICIN HCL

AP	BIGMAR	EQ 20MG BASE/VIAL	N65000 001	MAY 25, 1999

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DDAVP

AB	+ RHONE POULENC RORER	0.01MG/SPRAY	N17922 003	AUG 07, 1996
	*	0.01MG/SPRAY	N17922 003	AUG 07, 1996

DESMOPRESSIN ACETATE

AB	BAUSCH AND LOMB	0.01MG/SPRAY	N74830 001	JAN 25, 1999

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
DESOGESTREL AND ETHINYL ESTRADIOL

>ADD>	AB	DURAMED	0.15MG;0.03MG	N75256 001	AUG 12, 1999

ORTHO-CEPT

>ADD>	AB	+ JOHNSON RW	0.15MG;0.03MG	N20301 001	DEC 14, 1992

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
ORTHO-CEPT
> DLT > + JOHNSON RW 0.15MG;0.03MG N20301 001
> DLT > DEC 14, 1992

TABLET; ORAL-28
> ADD > DESOGESTREL AND ETHINYL ESTRADIOL
> ADD > AB DURAMED 0.15MG;0.03MG N75256 002
> ADD > AUG 12, 1999

DEXAMETHASONE

SUSPENSION/DROPS; OPHTHALMIC
DEXAMETHASONE
AT STERIS 0.1% N89170 001
MAY 09, 1989
@ 0.1% N89170 001
MAY 09, 1989
MAXIDEX
AT + ALCON 0.1% N13422 001
+ 0.1% N13422 001

TABLET; ORAL
> DLT > DEXONE 0.5
> DLT > BP SOLVAY 0.5MG N84991 001
> ADD > @ 0.5MG N84991 001
> DLT > DEXONE 0.75
> DLT > BP SOLVAY 0.75MG N84993 001
> ADD > @ 0.75MG N84993 001
> DLT > DEXONE 4
> DLT > BP SOLVAY 4MG N84992 001
> ADD > @ 4MG N84992 001

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
MAXITROL
AT + ALCON 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N50065 002
AT + FALCON PHARMS 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N50065 002

SUSPENSION/DROPS; OPHTHALMIC
MAXITROL
AT + ALCON 0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N50023 002

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
MAXITROL
AT + FALCON PHARMS 0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N50023 002

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DECADRON
AP + MERCK EQ 24MG PHOSPHATE/ML N12071 004
+ EQ 24MG PHOSPHATE/ML N12071 004
DEXAMETHASONE SODIUM PHOSPHATE
AP STERIS EQ 4MG PHOSPHATE/ML N83702 001
AP EQ 24MG PHOSPHATE/ML N85606 001
@ EQ 4MG PHOSPHATE/ML N83702 001
@ EQ 24MG PHOSPHATE/ML N85606 001

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE
AA ENDO PHARMS 5MG N40299 001
MAY 13, 1999

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN 2.5GM/100ML;450MG/100ML N18030 001
@ 2.5GM/100ML;450MG/100ML N18030 001
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML N18030 005
@ 5GM/100ML;110MG/100ML N18030 005
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML;200MG/100ML N18030 004
@ 5GM/100ML;200MG/100ML N18030 004
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML;330MG/100ML N18030 003
@ 5GM/100ML;330MG/100ML N18030 003
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN 5GM/100ML;450MG/100ML N18030 002
@ 5GM/100ML;450MG/100ML N18030 002

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

> DLT >		MD-76			
> DLT >	AP	MALLINCKRODT	66%;10%		N87073 001
> ADD >		@	66%;10%		N87073 001

DIAZEPAM

GEL; RECTAL

DIASTAT

+	ATHENA	2.5MG/0.5ML		N20648 001 JUL 29, 1997
		5MG/ML		N20648 002 JUL 29, 1997
		10MG/2ML		N20648 003 JUL 29, 1997
		15MG/3ML		N20648 004 JUL 29, 1997
+		20MG/4ML		N20648 005 JUL 29, 1997
+	ELAN PHARMS	2.5MG/0.5ML		N20648 001 JUL 29, 1997
		5MG/ML		N20648 002 JUL 29, 1997
		10MG/2ML		N20648 003 JUL 29, 1997
		15MG/3ML		N20648 004 JUL 29, 1997
+		20MG/4ML		N20648 005 JUL 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

AP	STERIS	5MG/ML		N70911 001 AUG 28, 1986
AP		5MG/ML		N70930 001 DEC 01, 1986
	@	5MG/ML		N70911 001 AUG 28, 1986
	@	5MG/ML		N70930 001 DEC 01, 1986

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

AB	MYLAN	50MG		N75463 001 JUL 26, 1999

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

AB	ALCON	0.1%		N20809 001 MAY 04, 1998
AB	FALCON PHARMS	0.1%	†	N20809 001 MAY 04, 1998

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB	MARTEC	50MG		N74986 001 FEB 26, 1999
AB		75MG		N74986 002 FEB 26, 1999
AB	NOVOPHARM	50MG		N74723 001 MAR 30, 1999
AB	SIDMAK LABS NJ	50MG		N74432 002 JUL 29, 1999
AB		75MG		N74432 003 JUL 29, 1999

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL

DICYCLOMINE HCL

AB	LANNETT	20MG		N40230 001 FEB 26, 1999

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

AB	TARO	0.05%		N75331 001 MAY 14, 1999

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB	ALTANA	0.05%		N75374 001 APR 27, 1999

† SEE SECTION 1.3 OF INTRODUCTION

† SEE SECTION 1.3 OF INTRODUCTION

DIFLORASONE DIACETATE

OINTMENT; TOPICAL

	DIFLORASONE DIACETATE			
AB	TARO	0.05%	N75331 001	MAY 14, 1999
	PSORCON			
AB +	PHARMACIA AND UPJOHN	0.05%	N19260 001	AUG 28, 1985
+		0.05%	N19260 001	AUG 28, 1985

DIFLUNISAL

TABLET; ORAL

	DIFLUNISAL			
AB	PUREPAC PHARM	250MG	N74285 001	MAY 07, 1996
AB		500MG	N74285 002	MAY 07, 1996
@		250MG	N74285 001	MAY 07, 1996
@		500MG	N74285 002	MAY 07, 1996

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CARDIZEM CD			
AB3 +	CARDERM	120MG	N20062 001	AUG 10, 1992
AB3 +		180MG	N20062 002	DEC 27, 1991
AB3 +		240MG	N20062 003	DEC 27, 1991
AB3 +		300MG	N20062 004	DEC 27, 1991
BC +		120MG	N20062 001	AUG 10, 1992
BC +		180MG	N20062 002	DEC 27, 1991
BC +		240MG	N20062 003	DEC 27, 1991
BC +		300MG	N20062 004	DEC 27, 1991
	CARTIA XT			
AB3	ANDRX PHARMS	120MG	N74752 002	JUL 09, 1998

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CARTIA XT			
AB3	ANDRX PHARMS	180MG	N74752 001	JUL 09, 1998
AB3		240MG	N74752 003	JUL 09, 1998
AB3		300MG	N74752 004	JUL 09, 1998
@		120MG	N74752 002	JUL 09, 1998
@		180MG	N74752 001	JUL 09, 1998
@		240MG	N74752 003	JUL 09, 1998
@		300MG	N74752 004	JUL 09, 1998

INJECTABLE; INJECTION

	DILTIAZEM HCL			
AP	MERIDIAN MEDCL TECHN	5MG/ML	N75106 001	APR 29, 1999

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

	HYDRAMINE			
AA	ALPHARMA	12.5MG/5ML	N80763 002	
@		12.5MG/5ML	N80763 002	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	DIPIVEFRIN HCL			
AT	ALCON	0.1%	N73636 001	JUN 30, 1994
AT	FALCON PHARMS	0.1%	N73636 001	JUN 30, 1994

DIPYRIDAMOLE

TABLET; ORAL

	DIPYRIDAMOLE			
AB	PUREPAC PHARM	25MG	N89425 001	JUL 12, 1990

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE
@ PUREPAC PHARM 25MG N89425 001 JUL 12, 1990 >ADD>

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL
DYNABAC
+ LILLY 250MG N50678 001 JUN 19, 1995
+ LILLY RES LABS 250MG N50678 001 JUN 19, 1995

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL
AP SMITH AND NEPHEW 40MG/ML N70046 001 AUG 29, 1985
AP 80MG/ML N70047 001 AUG 29, 1985
@ 40MG/ML N70046 001 AUG 29, 1985
@ 80MG/ML N70047 001 AUG 29, 1985

DOXERCALCIFEROL

CAPSULE; ORAL
HECTOROL
+ BONE CARE 2.5 UGM N20862 001 JUN 09, 1999 >ADD>

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL; INJECTION
DOXIL
+ ALZA 2MG/ML N50718 001 NOV 17, 1995
+ SEQUUS 2MG/ML N50718 001 NOV 17, 1995

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
BENDECTIN
@ HOECHST MARION RSSL 10MG;10MG N10598 002 >ADD>

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL
AP SOLOPAK 2.5MG/ML N71754 001 SEP 06, 1988
AP 2.5MG/ML N71755 001 SEP 06, 1988
@ 2.5MG/ML N71754 001 SEP 06, 1988
@ 2.5MG/ML N71755 001 SEP 06, 1988
AP STERIS 2.5MG/ML N73520 001 NOV 27, 1991
AP 2.5MG/ML N73521 001 NOV 27, 1991
AP 2.5MG/ML N73523 001 NOV 27, 1991
@ 2.5MG/ML N73520 001 NOV 27, 1991
@ 2.5MG/ML N73521 001 NOV 27, 1991
@ 2.5MG/ML N73523 001 NOV 27, 1991

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
LEXXEL
+ ASTRA PHARMS 5MG;2.5MG N20668 002 OCT 28, 1998 >ADD>

EPINEPHRINE

INJECTABLE; INJECTION
SUS-PHRINE
+ FOREST LABS 5MG/ML N07942 001
SUS-PHRINE SULFITE-FREE
FOREST LABS 1.5MG/AMP N07942 003 FEB 05, 1999

EPINEPHRINE

INJECTABLE; INJECTION
SUS-PHRINE SULFITE-FREE
+ FOREST LABS 5MG/ML N07942 001

ERGOTAMINE TARTRATE

> DLT > AEROSOL, METERED; INHALATION
> DLT > MEDIHALER ERGOTAMINE
> DLT > + 3M 0.36MG/INH N12102 001
> ADD > @ 0.36MG/INH N12102 001

ERYTHROMYCIN

SOLUTION; TOPICAL
C-SOLVE-2
> ADD > AT BIOGLAN PHAR 2% N62468 001
> ADD > JUL 03, 1985
> DLT > AT ZENITH GOLDLINE 2% N62468 001
> DLT > JUL 03, 1985

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
CLIMARA
BX + BERLEX LABS 0.025MG/24HR N20375 004
MAR 05, 1999

ESTRADIOL
AB MENOREST 0.0375MG/24HR N20538 001
JUL 31, 1996
AB 0.05MG/24HR N20538 003
JUL 31, 1996
AB 0.075MG/24HR N20538 002
JUL 31, 1996
AB 0.1MG/24HR N20538 004
JUL 31, 1996

VIVELLE-DOT
AB NOVARTIS 0.0375MG/24HR N20538 001
JUL 31, 1996
AB 0.05MG/24HR N20538 003
JUL 31, 1996
AB 0.075MG/24HR N20538 002
JUL 31, 1996
AB 0.1MG/24HR N20538 004
JUL 31, 1996

ESTRADIOL

TABLET; ORAL
ESTRADIOL
AB MYLAN 0.5MG N40326 001
APR 21, 1999
AB 1MG N40326 002
APR 21, 1999
AB 2MG N40326 003
APR 21, 1999

TABLET; VAGINAL
VAGIFEM
+ NOVO NORDISK 25 UGM N20908 001
MAR 26, 1999

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL
CENESTIN
DURAMED 0.9MG N20992 003
MAR 24, 1999
0.625MG N20992 002
MAR 24, 1999
+ 0.9MG N20992 003
MAR 24, 1999

ESTRONE

INJECTABLE; INJECTION
NATURAL ESTROGENIC SUBSTANCE-ESTRONE
+ STERIS 2MG/ML N85237 001
NOV 23, 1982
@ 2MG/ML N85237 001
NOV 23, 1982

ESTROPIPATE

CREAM; VAGINAL
OGEN
+ ABBOTT 1.5MG/GM N84710 001
+ PHARMACIA AND UPJOHN 1.5MG/GM N84710 001

TABLET; ORAL
ESTROPIPATE
> ADD > AB MYLAN 0.75MG N40359 001
> ADD > AUG 26, 1999

ESTROPIPATE

TABLET; ORAL

		ESTROPIPATE			
> ADD >	AB	MYLAN	1.5MG	N40359 002	
> ADD				AUG 26, 1999	
> ADD >	AB		3MG	N40359 003	
> ADD >				AUG 26, 1999	
		OGEN .625			
	AB	ABBOTT	0.75MG	N83220 001	
	AB	PHARMACIA AND UPJOHN	0.75MG	N83220 001	
		OGEN 1.25			
	AB	ABBOTT	1.5MG	N83220 002	
	AB	PHARMACIA AND UPJOHN	1.5MG	N83220 002	
		OGEN 2.5			
	AB +	ABBOTT	3MG	N83220 003	
	AB +	PHARMACIA AND UPJOHN	3MG	N83220 003	
		OGEN 5			
	AB	ABBOTT	6MG	N83220 004	
	AB	PHARMACIA AND UPJOHN	6MG	N83220 004	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	LEVLITE			
	BERLEX LABS	0.02MG;0.1MG	N20860 001	
			JUL 13, 1998	
+		0.02MG;0.1MG	N20860 001	
			JUL 13, 1998	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	BREVICON 21-DAY			
AB	SEARLE	0.035MG;0.5MG	N17566 001	
AB	WATSON LABS	0.035MG;0.5MG	N17566 001	
	NORINYL 1+35 21-DAY			
AB	SEARLE	0.035MG;1MG	N17565 001	
AB	WATSON LABS	0.035MG;1MG	N17565 001	
	TRI-NORINYL 21-DAY			
+	SEARLE	0.035MG,0.035MG;0.5MG,1MG	N18977 001	
			APR 13, 1984	
+	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977 001	
			APR 13, 1984	

TABLET; ORAL-28

	BREVICON 28-DAY			
AB	SEARLE	0.035MG;0.5MG	N17743 001	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

	BREVICON 28-DAY			
AB	WATSON LABS	0.035MG;0.5MG	N17743 001	
	NORINYL 1+35 28-DAY			
AB	SEARLE	0.035MG;1MG	N17565 002	
AB	WATSON LABS	0.035MG;1MG	N17565 002	
	TRI-NORINYL 28-DAY			
	SEARLE	0.035MG,0.035MG;0.5MG,1MG	N18977 002	
			APR 13, 1984	
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N18977 002	
			APR 13, 1984	

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

	LO/OVRAL			
AB +	WYETH AYERST	0.03MG;0.3MG	N17612 001	
*		0.03MG;0.3MG	N17612 001	
	LOW-OGESTREL-21			
AB	SCS	0.03MG;0.3MG	N75288 001	
			JUL 28, 1999	

TABLET; ORAL-28

	LO/OVRAL-28			
AB	WYETH AYERST	0.03MG;0.3MG	N17802 001	
		0.03MG;0.3MG	N17802 001	
	LOW-OGESTREL-28			
AB	SCS	0.03MG;0.3MG	N75288 002	
			JUL 28, 1999	

ETODOLAC

TABLET; ORAL

	ETODOLAC			
> ADD >	AB	EON	500MG	N74903 002
> ADD >				APR 19, 1999
	AB	NOVOPHARM	400MG	N74847 001
				APR 23, 1999
	AB		500MG	N74847 002
				APR 23, 1999

TABLET; ORAL-28
BREVICON 28-DAY
AB SEARLE 0.035MG;0.5MG N17743 001

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

>ADD>	AP	AM PHARM PARTNERS	20MG/ML	N74983 001 SEP 30, 1998	>DLT>	
>ADD>					>DLT>	
>DLT>	AP	APPLIED ANAL	20MG/ML	N74983 001 SEP 30, 1998	>ADD>	
>DLT>					>ADD>	
	AP	STERIS	20MG/ML	N74228 001 OCT 15, 1996	>ADD>	
					>ADD>	
	@		20MG/ML	N74228 001 OCT 15, 1996	>ADD>	
					>ADD>	

VEPESID

AP	+	BRISTOL	20MG/ML	N18768 001 NOV 10, 1983	
AP	+	BRISTOL MYERS SQUIBB	20MG/ML	N18768 001 NOV 10, 1983	

FERRIC SODIUM GLUCONATE

INJECTABLE; INJECTION
FERRLECIT

	+	R AND D LABS	62.5MG/5ML	N20955 001 FEB 18, 1999

FLUOCINONIDE

OINTMENT; TOPICAL
FLUOCINONIDE

AB		TARO	0.05%	N75008 001 JUN 30, 1999

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

AP		BIGMAR	50MG/ML	N40291 001 MAR 24, 1999
AP		SMITH AND NEPHEW	50MG/ML	N88767 001 DEC 28, 1984
AP			50MG/ML	N89434 001 MAR 26, 1987
	@		50MG/ML	N88767 001 DEC 28, 1984
	@		50MG/ML	N89434 001 MAR 26, 1987

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
PROZAC

	*	LILLY	EQ 20MG BASE	N18936 001 DEC 29, 1987
			EQ 20MG BASE	N18936 001 DEC 29, 1987
	+		EQ 40MG BASE	N18936 003 JUN 15, 1999
	@		EQ 60MG BASE	N18936 004 JUN 15, 1999

TABLET; ORAL
PROZAC

		LILLY	EQ 10MG BASE	N20974 001 MAR 09, 1999
	*		EQ 20MG BASE	N20974 002 MAR 09, 1999
	+		EQ 10MG BASE	N20974 001 MAR 09, 1999
	@		EQ 20MG BASE	N20974 002 MAR 09, 1999

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

AP		ABBOTT	10MG/ML	N75241 001 MAY 28, 1999
AP		SMITH AND NEPHEW	10MG/ML	N70078 001 FEB 05, 1986
	@		10MG/ML	N70078 001 FEB 05, 1986
AP		STERIS	10MG/ML	N70019 001 SEP 22, 1986
AP			10MG/ML	N70604 001 JAN 02, 1987
	@		10MG/ML	N70019 001 SEP 22, 1986
	@		10MG/ML	N70604 001 JAN 02, 1987

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION
FLAXEDIL

	*	DAVIS AND GECK	20MG/ML	N07842 001

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION
FLAXEDIL
+ DAVIS AND GECK — 100MG/ML — N07842 002 — > DLT >
@ — 20MG/ML — N07842 001 — > DLT >
@ — 100MG/ML — N07842 002 — > ADD >
> ADD >

GALLIUM NITRATE

INJECTABLE; INJECTION
GANITE
+ SOLOPAK — 25MG/ML — N19961 002 JAN 17, 1991
@ — 25MG/ML — N19961 002 JAN 17, 1991

GANIRELIX ACETATE

INJECTABLE; INJECTION
ANTAGON
+ ORGANON INC — EQ 250 UGM BASE/0.5ML — N21057 001 JUL 29, 1999

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE

AP	SOLOPAK	EQ 10MG BASE/ML	N62507 001 JUN 06, 1985
AP		EQ 40MG BASE/ML	N62507 002 JUN 06, 1985
@		EQ 10MG BASE/ML	N62507 001 JUN 06, 1985
@		EQ 40MG BASE/ML	N62507 002 JUN 06, 1985

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

AT	ALCON	EQ 0.3% BASE	N62196 001
AT	FALCON PHARMS	EQ 0.3% BASE	N62196 001

GLIPIZIDE

TABLET; ORAL
GLUCOTROL
PFIZER — 2.5MG — N17783 003 MAY 11, 1993
@ — 2.5MG — N17783 003 MAY 11, 1993

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

AB	MOVA	4.5MG	N74591 003 DEC 22, 1997
		4.5MG	N74591 003 DEC 22, 1997
AB	MYLAN	6MG	N74792 003 AUG 17, 1999
AB	NOVOPHARM	1.5MG	N74686 001 APR 20, 1999
AB		3MG	N74686 002 APR 20, 1999
AB		4.5MG	N74686 003 APR 20, 1999
AB		6MG	N74686 004 APR 20, 1999

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

AP	STERIS	0.2MG/ML	N86947 001 JUN 24, 1983
@		0.2MG/ML	N86947 001 JUN 24, 1983

TABLET; ORAL
ROBINUL
+ HORIZON PHARM — 1MG — N12827 001
+ ROBINS AH — 1MG — N12827 001
ROBINUL FORTE
+ HORIZON PHARM — 2MG — N12827 002
+ ROBINS AH — 2MG — N12827 002

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	STERIS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62788 001 JUN 11, 1987
@		0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62788 001 JUN 11, 1987

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75393 001 MAY 11, 1999
AO		EQ 100MG BASE/ML	N75393 002 MAY 11, 1999

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

AP	SOLOPAK	EQ 5MG BASE/ML	N70801 001 DEC 14, 1987
AP		EQ 5MG BASE/ML	N70864 001 DEC 14, 1987
@		EQ 5MG BASE/ML	N70801 001 DEC 14, 1987
@		EQ 5MG BASE/ML	N70864 001 DEC 14, 1987
AP	STERIS	EQ 5MG BASE/ML	N70713 001 MAY 17, 1988
AP		EQ 5MG BASE/ML	N70744 001 MAY 17, 1988
@		EQ 5MG BASE/ML	N70713 001 MAY 17, 1988
@		EQ 5MG BASE/ML	N70744 001 MAY 17, 1988

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

AP	SMITH AND NEPHEW	10 UNITS/ML	N88458 001 JUL 26, 1984

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

AP	SMITH AND NEPHEW	10 UNITS/ML	N88580 001 OCT 25, 1984
AP		100 UNITS/ML	N88460 001 JUL 26, 1984
AP		100 UNITS/ML	N88581 001 OCT 25, 1984
@		10 UNITS/ML	N88458 001 JUL 26, 1984
@		10 UNITS/ML	N88580 001 OCT 25, 1984
@		100 UNITS/ML	N88460 001 JUL 26, 1984
@		100 UNITS/ML	N88581 001 OCT 25, 1984
AP	SOLOPAK	100 UNITS/ML	N88459 001 JUL 26, 1984
@		100 UNITS/ML	N88459 001 JUL 26, 1984

HEPARIN SODIUM

AP	SMITH AND NEPHEW	1,000 UNITS/ML	N88239 001 JUL 26, 1984
@		1,000 UNITS/ML	N88239 001 JUL 26, 1984

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	HALSEY	1.5MG/5ML;5MG/5ML	N40285 001 JUL 19, 1999

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HCL

AP	+ LUITPOLD	20MG/ML	N40136 001 JUN 30, 1997
+		20MG/ML	N40136 001 JUN 30, 1997
AP	SOLOPAK	20MG/ML	N88517 001 AUG 22, 1985
@		20MG/ML	N88517 001 AUG 22, 1985

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

> DLT >	AB	SOLVAY	25MG;25MG	N87608 001
> DLT >				FEB 08, 1982
> DLT >	AB		50MG;50MG	N87213 001
> DLT >				FEB 08, 1982
> ADD >		@	25MG;25MG	N87608 001
> ADD >				FEB 08, 1982
> ADD >		@	50MG;50MG	N87213 001
> ADD >				FEB 08, 1982

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

> DLT >	BP	SOLVAY	25MG;15MG;0.1MG	N88376 001
> DLT >				OCT 28, 1983
> ADD >		@	25MG;15MG;0.1MG	N88376 001
> ADD >				OCT 28, 1983

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

@	SANOFI SYNTHELABO	12.5MG;75MG	N20758 001
			SEP 30, 1997
		12.5MG;150MG	N20758 002
			SEP 30, 1997
+		12.5MG;300MG	N20758 003
			AUG 31, 1998

AVAPRO HCT

@	SANOFI	12.5MG;75MG	N20758 001
			SEP 30, 1997
+		12.5MG;150MG	N20758 002
			SEP 30, 1997

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		DURAMED	25MG;37.5MG	N75052 001
				JUN 18, 1999

HYDROCORTISONE

ENEMA; RECTAL

CORTENEMA

AB	+	SOLVAY	100MG/60ML	N16199 001
BR	+		100MG/60ML	N16199 001

HYDROCORTISONE

AB	COPLEY PHARM	100MG/60ML	N74171 001
			MAY 27, 1994
BR		100MG/60ML	N74171 001
			MAY 27, 1994

LOTION; TOPICAL

> DLT >		DERMACORT		
> DLT >	AT	SOLVAY	0.5%	N84573 002
> DLT >	AT		1%	N86462 001
> ADD >		@	0.5%	N84573 002
> ADD >		@	1%	N86462 001

HYDROCORTISONE

AT	THAMES	2.5%	N40247 001
			JUL 23, 1999

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HYDROCORTISONE ACETATE

+	FERNDALE LABS	2.5%	N40259 001
			JUL 29, 1999

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

AP	STERIS	EQ 100MG BASE/VIAL	N84737 002
AP		EQ 100MG BASE/VIAL	N84738 001
AP		EQ 250MG BASE/VIAL	N84737 001
AP		EQ 500MG BASE/VIAL	N84747 001
AP		EQ 1GM BASE/VIAL	N84748 001
	@	EQ 100MG BASE/VIAL	N84737 002
	@	EQ 100MG BASE/VIAL	N84738 001
	@	EQ 250MG BASE/VIAL	N84737 001
	@	EQ 500MG BASE/VIAL	N84747 001
	@	EQ 1GM BASE/VIAL	N84748 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

	PAREDRINE			
	+ AKORN	1%		N00004 004
	+ PHARMICS	1%		N00004 004

HYDROXYUREA

CAPSULE; ORAL

	HYDROXYUREA			
AB	PAR PHARM	500MG		N75340 001 FEB 24, 1999

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE HCL			
AP	SOLOPAK	25MG/ML		N87591 001
AP		50MG/ML		N87593 001
AP		50MG/ML		N87595 001
	@	25MG/ML		N87591 001
	@	50MG/ML		N87593 001
	@	50MG/ML		N87595 001

IBUPROFEN

SUSPENSION; ORAL

	MOTRIN			
AB	+ MCNEIL	100MG/5ML		N19842 001 SEP 19, 1989
AB	+ MCNEIL CONS	100MG/5ML		N19842 001 SEP 19, 1989

TABLET; ORAL

	IBUPROFEN			
AB	NORTON HN	400MG		N71145 001 SEP 23, 1986
AB		600MG		N71146 001 SEP 23, 1986
AB		800MG		N71769 001 MAY 08, 1987
AB	ZENITH GOLDLINE	400MG		N71145 001 SEP 23, 1986
AB		600MG		N71146 001 SEP 23, 1986

IBUPROFEN

TABLET; ORAL

	IBUPROFEN			
AB	ZENITH GOLDLINE	800MG		N71769 001 MAY 08, 1987
	MOTRIN			
AB	MCNEIL	300MG		N17463 003
AB		400MG		N17463 002
AB		600MG		N17463 004
AB	+	800MG		N17463 005 MAY 22, 1985
		100MG		N20418 001 NOV 16, 1994
AB	MCNEIL CONS	300MG		N17463 003
AB		400MG		N17463 002
AB		600MG		N17463 004
AB	+	800MG		N17463 005 MAY 22, 1985
		100MG		N20418 001 NOV 16, 1994

TABLET, CHEWABLE; ORAL

	MOTRIN			
	MCNEIL	50MG		N20135 001 NOV 16, 1994
	+	100MG		N20135 002 NOV 16, 1994
	MCNEIL CONS	50MG		N20135 001 NOV 16, 1994
	+	100MG		N20135 002 NOV 16, 1994

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

	INDOCIN SR			
AB	EON	75MG		N74464 001 MAY 28, 1998
AB	+ MERCK	75MG		N18185 001 FEB 23, 1982
	@	75MG		N18185 001 FEB 23, 1982
	INDOMETHACIN			
AB	EON LABS MFG	75MG		N74464 001 MAY 28, 1998

INSULIN HUMAN

INJECTABLE; INJECTION
VELOSULIN BR
+ NOVO NORDISK — 100 UNITS/ML — N21028 001 JUL 19, 1999

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE
AN ALPHARMA — 0.02% — N75111 001 APR 22, 1999 — >DLT> >ADD>

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL

AN		INTL MEDICATION	0.08%	N86651 002
AN			0.1%	N86651 003
AN	+		0.1%	N86651 003
AN			0.167%	N86651 005
AN	+		0.167%	N86651 005
AN			0.25%	N86651 007
AN	+		0.25%	N86651 007
	+		0.08%	N86651 002

ISOETHARINE HCL S/F

AN	*	DEY	0.08%	N89817 001 NOV 22, 1988
AN	*		0.1%	N89818 001 NOV 22, 1988
AN	*		0.17%	N89819 001 NOV 22, 1988
AN	*		0.25%	N89820 001 NOV 22, 1988
	@		0.08%	N89817 001 NOV 22, 1988
	@		0.1%	N89818 001 NOV 22, 1988
	@		0.17%	N89819 001 NOV 22, 1988
	@		0.25%	N89820 001 NOV 22, 1988

ISOFLURANE

LIQUID; INHALATION
FORANE

AN	+	BAXTER PHARM PROD	99.9%	N17624 001
AN	*	OHMEDA	99.9%	N17624 001

ISONIAZID; RIFAMPIN

CAPSULE; ORAL
RIFAMATE

	+	DOW PHARM	150MG;300MG	N61884 001
	+	HOECHST MARION RSSL	150MG;300MG	N61884 001

ISOSORBIDE DINITRATE

TABLET; ORAL
SORBITRATE

AB		ZENECA	30MG	N88124 001 AUG 21, 1990
	@		30MG	N88124 001 AUG 21, 1990

ISOTRETINOIN

CAPSULE; ORAL
ACCUTANE

		HLR	10MG	N18662 002 MAY 07, 1982
			20MG	N18662 004 MAR 28, 1983
	+		40MG	N18662 003 MAY 07, 1982
		ROCHE	10MG	N18662 002 MAY 07, 1982
			20MG	N18662 004 MAR 28, 1983
	*		40MG	N18662 003 MAY 07, 1982

ITRACONAZOLE

INJECTABLE; INJECTION
SPORANOX
+ JANSSEN — 10MG/ML — N20966 001 MAR 30, 1999

KANAMYCIN SULFATE

INJECTABLE; INJECTION

	KANAMYCIN SULFATE			
AP	**SOLOPAK**	**EQ 75MG BASE/2ML**	**N62605 003**	**FEB 26, 1986**
AP		**EQ 500MG BASE/2ML**	**N62605 001**	**FEB 26, 1986**
AP		**EQ 1GM BASE/3ML**	**N62605 002**	**FEB 26, 1986**
@		EQ 75MG BASE/2ML	N62605 003	FEB 26, 1986
@		EQ 500MG BASE/2ML	N62605 001	FEB 26, 1986
@		EQ 1GM BASE/3ML	N62605 002	FEB 26, 1986

KETOCONAZOLE

TABLET; ORAL

	KETOCONAZOLE			
AB	APPLIED ANAL	**200MG**	**N75341 001**	JUL 27, 1999
AB	MUTUAL PHARMA	**200MG**	**N75314 001**	JUN 15, 1999
AB	NOVOPHARM	**200MG**	**N74971 001**	JUN 15, 1999
AB	SIDMAK LABS CA	**200MG**	**N75362 001**	JUN 15, 1999
AB	TARO	**200MG**	**N75319 001**	JUN 15, 1999
AB	TEVA	**200MG**	**N75273 001**	JUN 15, 1999
	NIZORAL			
AB	+ JANSSEN	**200MG**	**N18533 001**	
	+	200MG	N18533 001	

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

	KETOPROFEN			
AB	ANDRX PHARMS	**100MG**	**N75270 002**	MAR 24, 1999
AB		**150MG**	**N75270 003**	MAR 24, 1999
AB		**200MG**	**N75270 001**	MAR 24, 1999

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

	ORUVAIL			
AB	WYETH AYERST	**100MG**	**N19816 003**	FEB 08, 1995
AB		**150MG**	**N19816 002**	FEB 08, 1995
		100MG	N19816 003	FEB 08, 1995
		150MG	N19816 002	FEB 08, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

	KETOROLAC TROMETHAMINE			
AP	ABBOTT	**15MG/ML**	**N74993 001**	JAN 27, 1999
AP		**30MG/ML**	**N74993 002**	JAN 27, 1999
AP	BEDFORD	**15MG/ML**	**N75222 001**	APR 26, 1999
AP		**30MG/ML**	**N75222 002**	APR 26, 1999
AP		**30MG/ML**	**N75228 001**	APR 26, 1999

TABLET; ORAL

	KETOROLAC TROMETHAMINE			
AB	SIDMAK LABS CA	**10MG**	**N75284 001**	JUN 23, 1999

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

	ZADITOR			
	+ CIBA	EQ 0.025% BASE	N21066 001	JUL 02, 1999

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

	LABETALOL HCL			
AP	BEDFORD	**5MG/ML**	**N75303 001**	MAY 28, 1999

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HCL

AB	MUTUAL PHARM	100MG		N75215 001 JUL 29, 1999	
AB		200MG		N75215 002 JUL 29, 1999	
AB		300MG		N75215 003 JUL 29, 1999	
	TRANDATE				
AB	FARO PHARMS	100MG		N18716 001 MAY 24, 1985	
AB		200MG		N18716 002 AUG 01, 1984	
AB		300MG		N18716 003 AUG 01, 1984	
@		400MG		N18716 004 AUG 01, 1984	
AB	GLAXO WELLCOME	100MG		N18716 001 MAY 24, 1985	
AB		200MG		N18716 002 AUG 01, 1984	
AB		300MG		N18716 003 AUG 01, 1984	
@		400MG		N18716 004 AUG 01, 1984	

LACTULOSE

SOLUTION; ORAL

LACTULOSE

> DLT > > DLT > > ADD > > ADD >	AA	PACO	10GM/15ML		N73160 001 AUG 25, 1992
	@		10GM/15ML	> ADD > > ADD >	N73160 001 AUG 25, 1992

SOLUTION; ORAL, RECTAL

LACTULOSE

> DLT > > DLT > > ADD > > ADD >	AA	PACO	10GM/15ML		N72029 001 AUG 25, 1992
	@		10GM/15ML	> ADD > > ADD >	N72029 001 AUG 25, 1992

LAMIVUDINE

SOLUTION; ORAL

EPIVIR-HBV

	+	GLAXO WELLCOME	5MG/ML		N20596 002 DEC 08, 1998
	+		5MG/ML	> ADD > > ADD >	N21004 001 DEC 08, 1998

TABLET; ORAL

EPIVIR-HBV

	+	GLAXO WELLCOME	100MG		N20564 002 DEC 08, 1998
	+		100MG	> ADD > > ADD >	N21003 001 DEC 08, 1998

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

AP	+	ABBOTT	EQ 10MG BASE/ML	> DLT > > DLT > > DLT >	N40147 001 JUN 25, 1997
AP	+	BEDFORD	EQ 200MG BASE/VIAL		N40056 001 MAY 23, 1995

LEUCOVORIN CALCIUM PRESERVATIVE FREE

	+	ABBOTT	EQ 10MG BASE/ML	> ADD > > ADD >	N40147 001 JUN 25, 1997
AP	+	BEDFORD	EQ 200MG BASE/VIAL		N40056 001 MAY 23, 1995
AP		BIGMAR	EQ 10MG BASE/ML	> DLT > > DLT >	N40286 001 FEB 26, 1999
AP			EQ 200MG BASE/VIAL		N40258 001 FEB 26, 1999
	+		EQ 500MG BASE/VIAL	> ADD > > ADD >	N40286 001 FEB 26, 1999
AP		GENSIA SICOR PHARMS	EQ 10MG BASE/ML		N40332 001 JUN 28, 1999

TABLET; ORAL

LEUCOVORIN CALCIUM

AB		INVAMED	EQ 15MG BASE		N75327 001 MAR 24, 1999

WELLCOVORIN

AB		GLAXO WELLCOME	EQ 5MG BASE		N18342 001 JUL 08, 1983

LEUCOVORIN CALCIUM

TABLET; ORAL
WELLCOVORIN

AB	+	GLAXO WELLCOME	EQ 25MG BASE	N18342 002 JUL 08, 1983	>DLT<
	@		EQ 5MG BASE	N18342 001 JUL 08, 1983	
	@		EQ 25MG BASE	N18342 002 JUL 08, 1983	

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
XOPENEX

	+	SEPRACOR	EQ 0.021% BASE	N20837 001 MAR 25, 1999
	+		EQ 0.042% BASE	N20837 002 MAR 25, 1999

>ADD< LEVOBUPIVACAINE HYDROCHLORIDE

>ADD< INJECTABLE; INJECTION
>ADD< CHIROCAINE

>ADD<		DARWIN DISCOVERY	EQ 2.5MG BASE/ML	N20997 001 AUG 05, 1999
>ADD<			EQ 5MG BASE/ML	N20997 002 AUG 05, 1999
>ADD<	+		EQ 7.5MG BASE/ML	N20997 003 AUG 05, 1999

LEVONORGESTREL

TABLET; ORAL
PLAN B

	+	WOMENS CAPITAL	0.75MG	N21045 001 JUL 28, 1999

LIDOCAINE

>ADD< FILM, EXTENDED RELEASE; TOPICAL
>ADD< LIDODERM

>ADD<	+	TEIKOKU PHARMA USA	700MG/12HR	N20612 001 MAR 19, 1999

LIDOCAINE

FILM, EXTENDED RELEASE; TRANSDERMAL
LIDODERM

>DLT<	+	HIND HLTHCARE	700MG/12HR	N20612 001 MAR 19, 1999

LIDOCAINE; PRILOCAINE

AEROSOL; TOPICAL
EMLA

	+	ASTRA PHARMS	2.5%;2.5%	N20962 001 FEB 04, 1998

DISC; TOPICAL
EMLA

	+	ASTRA PHARMS	2.5%;2.5%	N20962 001 FEB 04, 1998

LISINOPRIL

TABLET; ORAL
ZESTRIL

		ZENECA	30MG	N19777 006 JAN 20, 1999

LITHIUM CARBONATE

CAPSULE; ORAL
LITHONATE

AB		SOLVAY	300MG	N16782 001
	@		300MG	N16782 001

TABLET; ORAL
LITHIUM CARBONATE

AB		PFIZER	300MG	N16834 001
AB	+		300MG	N16834 001
		LITHOTABS		
AB	+	SOLVAY	300MG	N16980 001
	@		300MG	N16980 001

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
IMODIUM

AB	+	JANSSEN	2MG	N17694 001

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

	IMODIUM				
	@ JANSSEN				
AB	+ MCNEIL CONS	2MG	N17690 001	> ADD	
	@	2MG	N17694 001	> ADD	
		2MG	N17690 001		

LORACARBEF

CAPSULE; ORAL

	LORABID				
> ADD >	KING PHARMS	200MG	N50668 001		
> ADD >	+		DEC 31, 1991		
> ADD >		400MG	N50668 002		
> ADD >	LILLY		APR 05, 1996		
> DLT >		200MG	N50668 001		
> DLT >	+		DEC 31, 1991		
> DLT >		400MG	N50668 002		
			APR 05, 1996		

POWDER FOR RECONSTITUTION; ORAL

	LORABID				
> ADD >	KING PHARMS	100MG/5ML	N50667 001		
> ADD >	+		DEC 31, 1991		
> ADD >		200MG/5ML	N50667 002		
> ADD >	LILLY		DEC 31, 1991		
> DLT >		100MG/5ML	N50667 001		
> DLT >	+		DEC 31, 1991		
> DLT >		200MG/5ML	N50667 002		
			DEC 31, 1991		

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

	LOTEMAX				
	+ PHARMOS	0.5%	N20841 001		
	@		MAR 09, 1998		
		0.5%	N20841 001		
			MAR 09, 1998		

LUTEINIZING HORMONE; MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

	REPRONEX				
> ADD >	BX FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001		
> ADD >			AUG 27, 1999		

LUTEINIZING HORMONE; MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

	REPRONEX				
	FERRING	150 IU/VIAL;150 IU/VIAL	N21047 002		
			AUG 27, 1999		

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER			
B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19006 001	
@		APR 04, 1984	
	30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML	N19006 001	
		APR 04, 1984	

MALATHION

LOTION; TOPICAL

OVIDE			
@ MEDICIS	0.5%	N18613 001	
+		AUG 02, 1982	
	0.5%	N18613 001	
		AUG 02, 1982	

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 25%		
AP	STERIS	12.5GM/50ML	N87460 001
	@		JUN 27, 1983
		12.5GM/50ML	N87460 001
			JUN 27, 1983

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

	VERMOX		
AB	+ JANSSEN	100MG	N17481 001

MEBENDAZOLE

TABLET, CHEWABLE; ORAL
VERMOX
AB + MCNEIL CONS 100MG N17481 001

MECLOCYCLINE SULFOSALICYLATE

> DLT > CREAM; TOPICAL
> DLT > MECLAN
> DLT > + JOHNSON AND JOHNSON 1% N50518 001
> ADD > @ 1% N50518 001

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL
CYCRIN
BSI 2.5MG N81239 001 OCT 30, 1992
5MG N81240 001 OCT 30, 1992
10MG N89386 001 SEP 09, 1987
@ 2.5MG N81239 001 OCT 30, 1992
@ 5MG N81240 001 OCT 30, 1992
@ 10MG N89386 001 SEP 09, 1987

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DEMEROL
AP + ABBOTT 25MG/ML N05010 007
AP + 50MG/ML N05010 002
AP + 75MG/ML N05010 009
AP + 100MG/ML N05010 003
AP + SANOFI 25MG/ML N05010 007
AP + 50MG/ML N05010 002
AP + 75MG/ML N05010 009
AP + 100MG/ML N05010 003
MEPERIDINE HCL
AP + ABBOTT 10MG/ML N88432 001 AUG 16, 1984

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL
AP ASTRA PHARMS 10MG/ML N81002 001 JUL 30, 1993
AP INTL MEDICATION 10MG/ML N81309 001 AUG 30, 1993
AP MALLINCKRODT 10MG/ML N40163 001 MAY 12, 1997
AP STERIS 10MG/ML N73443 001 MAR 17, 1992
MEPERIDINE HCL PRESERVATIVE FREE
AP + ABBOTT 10MG/ML N88432 001 AUG 16, 1984
AP ASTRA PHARMS 10MG/ML N81002 001 JUL 30, 1993
AP FAULDING 10MG/ML N40305 001 MAR 10, 1999
AP INTL MEDICATION 10MG/ML N81309 001 AUG 30, 1993
AP MALLINCKRODT 10MG/ML N40163 001 MAY 12, 1997
AP STERIS 10MG/ML N73443 001 MAR 17, 1992

SYRUP; ORAL
DEMEROL
AA + ABBOTT 50MG/5ML N05010 005
AA + SANOFI 50MG/5ML N05010 005

TABLET; ORAL
DEMEROL
AA + ABBOTT 50MG N05010 001
AA + 100MG N05010 004
AA + SANOFI 50MG N05010 001
AA + 100MG N05010 004
MEPERIDINE HCL
AA AMIDE PHARM 50MG N40331 001 MAY 28, 1999
AA 100MG N40331 002 MAY 28, 1999

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION
MERSALYL-THEOPHYLLINE
+ STERIS 100MG/ML;50MG/ML N84875 001

MERSALYL SODIUM; THEOPHYLLINE

	INJECTABLE; INJECTION			
	MERSALYL-THEOPHYLLINE			
@	STERIS	100MG/ML;50MG/ML		N84875 001

METFORMIN HYDROCHLORIDE

	TABLET; ORAL			
	GLUCOPHAGE			
+	BRISTOL MYERS SQUIBB	500MG		N20357 001 MAR 03, 1995
		625MG		N20357 003 NOV 05, 1998
		750MG		N20357 004 NOV 05, 1998
		500MG		N20357 001 MAR 03, 1995
@		625MG		N20357 003 NOV 05, 1998
@		750MG		N20357 004 NOV 05, 1998

METHOTREXATE SODIUM

	INJECTABLE; INJECTION			
	METHOTREXATE			
AP	BIGMAR	EQ 25MG BASE/ML		N40263 001 FEB 26, 1999
	METHOTREXATE PRESERVATIVE FREE			
AP	BIGMAR	EQ 25MG BASE/ML		N40265 001 FEB 26, 1999
AP		EQ 1GM BASE/VIAL		N40266 001 FEB 26, 1999
	METHOTREXATE SODIUM			
+	LEDERLE	EQ 1GM BASE/VIAL		N11719 009 APR 07, 1988
	METHOTREXATE SODIUM PRESERVATIVE FREE			
AP +	LEDERLE	EQ 1GM BASE/VIAL		N11719 009 APR 07, 1988
	TABLET; ORAL			
	METHOTREXATE SODIUM			
AB	DURAMED	EQ 2.5MG BASE		N40233 001 JUN 17, 1999

METHOTRIMEPRAZINE

	INJECTABLE; INJECTION			
	LEVOPRONE			
+	IMMUNEX	20MG/ML		N15865 001
@		20MG/ML		N15865 001

METHOXSALEN

	INJECTABLE; INJECTION			
	UVADEX			
+	THERAKOS	0.02MG/ML		N20969 001 FEB 25, 1999

METHYLDOPATE HYDROCHLORIDE

	INJECTABLE; INJECTION			
	METHYLDOPATE HCL			
AP	SMITH AND NEPHEW	50MG/ML		N70841 001 JAN 02, 1987
@		50MG/ML		N70841 001 JAN 02, 1987

METHYLPREDNISOLONE SODIUM SUCCINATE

	INJECTABLE; INJECTION			
	METHYLPREDNISOLONE SODIUM SUCCINATE			
AP	STERIS	EQ 40MG BASE/VIAL		N86953 001 JUL 22, 1982
AP		EQ 125MG BASE/VIAL		N87030 001 JUL 22, 1982
AP		EQ 500MG BASE/VIAL		N88523 001 JUL 24, 1984
AP		EQ 1GM BASE/VIAL		N88524 001 JUL 24, 1984
@		EQ 40MG BASE/VIAL		N86953 001 JUL 22, 1982
@		EQ 125MG BASE/VIAL		N87030 001 JUL 22, 1982
@		EQ 500MG BASE/VIAL		N88523 001 JUL 24, 1984
@		EQ 1GM BASE/VIAL		N88524 001 JUL 24, 1984

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	SMITH AND NEPHEW	EQ 5MG BASE/ML	N70623 001	MAR 02, 1987
@		EQ 5MG BASE/ML	N70623 001	MAR 02, 1987

METOLAZONE

TABLET; ORAL
ZAROXOLYN

	MEDEVA	2.5MG	N17386 001	
+		2.5MG	N17386 001	

METRONIDAZOLE

INJECTABLE; INJECTION
FLAGYL I.V. RTU IN PLASTIC CONTAINER

> ADD >	AP	+	BAXTER HLTHCARE	500MG/100ML	N18657 001
> DLT >	AP	+	SCS	500MG/100ML	N18657 001

METRONIDAZOLE

AP	STERIS	500MG/100ML	N70170 001	APR 01, 1986
@		500MG/100ML	N70170 001	APR 01, 1986

MICONAZOLE NITRATE

INSERT, CREAM; VAGINAL, TOPICAL
MONISTAT DUAL- PAK

+	ADVANCED CARE PRODS	1.2GM,2%	N20968 001	JUN 30, 1999

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

AB	ALPHARMA US PHARM	200MG	N73508 001	NOV 19, 1993
AB	NMC	200MG	N73508 001	NOV 19, 1993

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL

	+	DANBURY PHARMA	EQ 75MG BASE		N63065 002 JUN 10, 1999
	AB	GLOBAL PHARM	EQ 50MG BASE		N65005 001 MAR 23, 1999
	AB		EQ 100MG BASE		N65005 002 MAR 23, 1999
> DLT >	AB	WARNER CHILCOTT	EQ 50MG BASE		N63066 001 AUG 14, 1990
> DLT >	AB		EQ 100MG BASE		N63067 001 JUL 31, 1990

VECTRIN

> ADD >	AB	WARNER CHILCOTT	EQ 50MG BASE	N63066 001 AUG 14, 1990
> ADD >	AB		EQ 100MG BASE	N63067 001 JUL 31, 1990

NADOLOL

TABLET; ORAL
CORGARD

AB	APOTHECON	20MG	N18063 005	OCT 28, 1986
AB		40MG	N18063 001	
AB		80MG	N18063 002	
AB		120MG	N18063 003	
AB	+	160MG	N18063 004	
AB	BRISTOL MYERS SQUIBB	20MG	N18063 005	OCT 28, 1986
AB		40MG	N18063 001	
AB		80MG	N18063 002	
AB		120MG	N18063 003	
AB	+	160MG	N18063 004	

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP	SMITH AND NEPHEW	0.02MG/ML	N71671 001	NOV 17, 1987
AP		0.4MG/ML	N71681 001	NOV 17, 1987
@		0.02MG/ML	N71671 001	NOV 17, 1987

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

	@ SMITH AND NEPHEW	0.4MG/ML	N71681 001	> DLT >	
			NOV 17, 1987	> ADD >	
AP	STERIS	0.4MG/ML	N71339 001		
			NOV 18, 1987		
	@	0.4MG/ML	N71339 001		
			NOV 18, 1987		

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL

AB	AMIDE PHARM	50MG	N75274 001		
			MAY 26, 1999		

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

				> DLT >	
				> DLT >	
				> DLT >	
				> DLT >	
AO	STERIS	50MG/ML	N88554 001	> ADD >	
			FEB 10, 1986	> ADD >	
	@	50MG/ML	N88554 001		
			FEB 10, 1986		

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION
DURABOLIN

AO	+ ORGANON	25MG/ML	N11891 001		
AO	+	50MG/ML	N11891 002		
	+	25MG/ML	N11891 001		
	+	50MG/ML	N11891 002		
	NANDROLONE PHENPROPIONATE				
AO	STERIS	25MG/ML	N86386 001		
			JUN 17, 1983		
AO		50MG/ML	N87488 001		
			JUN 17, 1983		
	@	25MG/ML	N86386 001		
			JUN 17, 1983		
	@	50MG/ML	N87488 001		
			JUN 17, 1983		

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
NAPHAZOLINE HCL

AT	AKORN	0.1%	N83590 001
AT	TAYLOR	0.1%	N83590 001

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN

AB	SIDMAK LABS CA	375MG	N75337 001
			MAY 26, 1999
AB		500MG	N75337 002
			MAY 26, 1999

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL
TPN SUSPENSION

	+ INTL MINERALS	15MG/5ML;3.75MG/5ML; 600MG/5ML	N08378 003
	@	15MG/5ML;3.75MG/5ML; 600MG/5ML	N08378 003

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP

	+ ELAN PHARM	11MG/24HR	N19983 001
			JAN 28, 1992
	+	22MG/24HR	N19983 002
			JAN 28, 1992
	@	11MG/24HR	N19983 001
			JAN 28, 1992
	@	22MG/24HR	N19983 002
			JAN 28, 1992

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN

AP	SMITH AND NEPHEW	5MG/ML	N70633 001
			JUN 19, 1986

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN
@ SMITH AND NEPHEW 5MG/ML N70633 001 JUN 19, 1986

OINTMENT; TRANSDERMAL
NITROGLYCERIN
ALTANA 2% N87355 001 JUL 08, 1988
+ 2% N87355 001 JUL 08, 1988

> ADD > SPRAY, METERED; SUBLINGUAL
> ADD > NITROLINGUAL PUMPSPRAY
> ADD > + POHL BOSKAMP 0.4MG/SPRAY N18705 002 JAN 10, 1997
> ADD >

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
+ ASTRA PHARMS 10MG N19810 003 OCT 05, 1995
10MG N19810 003 OCT 05, 1995

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ZOFRAN ODT
GLAXO WELLCOME EQ 4MG BASE N20781 001 JAN 27, 1999
+ EQ 8MG BASE N20781 002 JAN 27, 1999

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL
ZOFRAN
> DLT > + GLAXO WELLCOME EQ 8MG BASE N20103 002 DEC 31, 1992
> DLT >
> ADD > EQ 8MG BASE N20103 002 DEC 31, 1992
> ADD >

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL
ZOFRAN
> ADD > + GLAXO WELLCOME EQ 24MG BASE N20103 003 AUG 27, 1999
> ADD >

ORLISTAT

CAPSULE; ORAL
XENICAL
+ ROCHE 120MG N20766 001 APR 23, 1999

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
ORPHENADRINE CITRATE
AB KIEL 100MG N40249 001 JAN 29, 1999

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE
AA MIKART 5MG/5ML N75039 001 JAN 29, 1999

TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL
+ ALZA 15MG N20897 003 JUN 22, 1999

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL
TERRAMYCIN
+ PFIZER EQ 125MG BASE/5ML N60595 001
@ EQ 125MG BASE/5ML N60595 001

OXYTETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
TERRAMYCIN
+ PFIZER EQ 250MG BASE/VIAL N60586 001

OXYTETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
TERRAMYCIN
+ PFIZER — EQ 500MG BASE/VIAL — N60586 002
@ — EQ 250MG BASE/VIAL — N60586 001
@ — EQ 500MG BASE/VIAL — N60586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC
TERRAMYCIN W/ POLYMYXIN
+ PFIZER — EQ 5MG BASE/GM; 10,000 UNITS/GM — N61841 001
@ — EQ 5MG BASE/GM; 10,000 UNITS/GM — N61841 001

TABLET; VAGINAL
TERRAMYCIN-POLYMYXIN
+ PFIZER — EQ 100MG BASE; 100,000 UNITS — N61009 001
@ — EQ 100MG BASE; 100,000 UNITS — N61009 001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL
PAXIL
SMITHKLINE BEECHAM — EQ 10MG BASE — N20885 001 OCT 09, 1998
EQ 20MG BASE — N20885 002 OCT 09, 1998 > ADD >
EQ 30MG BASE — N20885 003 OCT 09, 1998 > ADD >
+ EQ 40MG BASE — N20885 004 OCT 09, 1998
@ EQ 10MG BASE — N20885 001 OCT 09, 1998
@ EQ 20MG BASE — N20885 002 OCT 09, 1998
@ EQ 30MG BASE — N20885 003 OCT 09, 1998
@ EQ 40MG BASE — N20885 004 OCT 09, 1998

TABLET, EXTENDED RELEASE; ORAL
PAXIL CR
+ SMITHKLINE BEECHAM — EQ 12.5MG BASE — N20936 001 FEB 16, 1999

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PAXIL CR
+ SMITHKLINE BEECHAM — EQ 25MG BASE — N20936 002 FEB 16, 1999

PEMOLINE

TABLET; ORAL
CYLERT
AB ABBOTT — 37.5MG — N16832 002
AB + — 75MG — N16832 003
18.75MG — N16832 001
37.5MG — N16832 002
+ 75MG — N16832 003
+ 18.75MG — N16832 001
PEMOLINE
AB COPLEY PHARM — 37.5MG — N75030 001 JAN 29, 1999
AB — 75MG — N75030 002 JAN 29, 1999
AB INVAMED — 37.5MG — N75286 002 JUN 30, 1999
AB — 75MG — N75286 003 JUN 30, 1999

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE
AB IMPAX PHARM — 400MG — N75093 001 AUG 10, 1999
AB SIDMAK LABS NJ — 400MG — N74874 001 MAY 25, 1999
AB TORPHARM — 400MG — N75191 001 JUN 09, 1999
PENTOXIL
AB UPSHER SMITH — 400MG — N74962 001 MAR 31, 1999

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON
@ HUESCHEN — 2MG — N20184 001 DEC 30, 1993

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

	@	HUESCHEN	4MG	N20184 002 DEC 30, 1993
	@		8MG	N20184 003 DEC 30, 1993
	@	SOLVAY	2MG	N20184 001 DEC 30, 1993
	@		4MG	N20184 002 DEC 30, 1993
	@		8MG	N20184 003 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA		MFG CHEMISTS	35MG	N85914 001
	@		35MG	N85914 001
AA		PVT FORM	35MG	N85697 001
	@		35MG	N85697 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
FASTIN

AA	+	SMITHKLINE BEECHAM	30MG	N17352 001
	@		30MG	N17352 001

PHENTERMINE HCL

AA		EON	30MG	N86945 001 JUL 20, 1983
AA	+		30MG	N86945 001 JUL 20, 1983

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

AP		STERIS	50MG/ML	N85434 001
	@		50MG/ML	N85434 001

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
ACTOS

		TAKEDA	EQ 15MG BASE	N21073 001 JUL 15, 1999
			EQ 30MG BASE	N21073 002 JUL 15, 1999
	+		EQ 45MG BASE	N21073 003 JUL 15, 1999

POLYETHYLENE GLYCOL 3350

POWDER FOR RECONSTITUTION; ORAL
MIRALAX

	+	BRAINTREE	17GM/SCOOPFUL	N20698 001 FEB 18, 1999

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		ALCON	10,000 UNITS/ML; EQ 1MG BASE/ML	N64211 001 APR 13, 1998
AT		FALCON PHARMS	10,000 UNITS/ML; EQ 1MG BASE/ML	N64211 001 APR 13, 1998

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
MICRO-K

AB		KV PHARM	8MEQ	N18238 001
AB		ROBINS AH	8MEQ	N18238 001

MICRO-K 10

AB	+	KV PHARM	10MEQ	N18238 002 MAY 14, 1984
AB	+	ROBINS AH	10MEQ	N18238 002 MAY 14, 1984

GRANULE, FOR RECONSTITUTION ER; ORAL
MICRO-K LS

	@	KV PHARM	20MEQ/PACKET	N19561 003 AUG 26, 1988

POTASSIUM CHLORIDE

GRANULE, FOR RECONSTITUTION ER; ORAL

MICRO-K LS				
@ ROBINS AH	20MEQ/PACKET	N19561 003 AUG 26, 1988	> ADD > > ADD > > DLT > > DLT >	

INJECTABLE; INJECTION

POTASSIUM CHLORIDE				
AP AM PHARM PARTNERS	3MEQ/ML	N80225 003		
+	3MEQ/ML	N80225 003		
AP STERIS	2MEQ/ML	N86208 001		
AP	2MEQ/ML	N89163 001 MAR 10, 1988		
AP	2MEQ/ML	N89421 001 JAN 02, 1987	> DLT > > DLT >	
AP	3MEQ/ML	N86210 001	> ADD >	
AP +	2MEQ/ML	N86208 001	> ADD >	
@	2MEQ/ML	N89163 001 MAR 10, 1988	> DLT > > DLT >	
@	2MEQ/ML	N89421 001 JAN 02, 1987	> ADD > > ADD >	
@	3MEQ/ML	N86210 001		

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E		
+ ABBOTT	370MG/VIAL;1.75GM/VIAL; 36GM/VIAL	N13025 001
@	370MG/VIAL;1.75GM/VIAL; 36GM/VIAL	N13025 001

POTASSIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL

POTASSIUM CITRATE		
@ MISSION PHARMA	10MEQ/PACKET	N19647 002 OCT 13, 1988
@	20MEQ/PACKET	N19647 001 OCT 13, 1988
@ UNIV TX	10MEQ/PACKET	N19647 002 OCT 13, 1988
@	20MEQ/PACKET	N19647 001 OCT 13, 1988

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC

BETADINE		
+ ALCON UNIVERSAL	5%	N18634 001 DEC 17, 1986
+ PURDUE FREDERICK	5%	N18634 001 DEC 17, 1986

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HCL			
AB ZENITH GOLDLINE	EQ 2MG BASE	N71995 001 MAY 16, 1989	
AB	EQ 2MG BASE	N71995 001 SEP 12, 1988	
AB	EQ 5MG BASE	N71745 001 MAY 16, 1989	
AB	EQ 5MG BASE	N71745 001 SEP 12, 1988	

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE			
AA HALSEY	15MG/5ML	N40287 001 MAY 28, 1999	
AA UDL	15MG/5ML	N40323 001 MAY 13, 1999	

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

PREDNISOLONE ACETATE		
+ STERIS	40MG/ML	N83767 001
@	40MG/ML	N83767 001

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED PLUS		
AB ALCON	1%	N17469 001
AB FALCON PHARMS	1%	N17469 001

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
HYDELTRASOL
+ MERCK — EQ 20MG PHOSPHATE/ML — N11583 002
@ — EQ 20MG PHOSPHATE/ML — N11583 002

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION
HYDELTRA-TBA
BP + MERCK — 20MG/ML — N10562 001
+ — 20MG/ML — N10562 001
PREDNISOLONE TEBUTATE
BP STERIS — 20MG/ML — N83362 001 FEB 17, 1984
@ — 20MG/ML — N83362 001 FEB 17, 1984

PREDNISONE

TABLET; ORAL
ORASONE
> DLT > AB SOLVAY — 50MG — N85999 001
> ADD > @ — 50MG — N85999 001

PROBENECID

TABLET; ORAL
BENEMID
AB + MERCK — 500MG — N07898 004
@ — 500MG — N07898 004
PROBENECID
AB MYLAN — 500MG — N84211 002
AB + — 500MG — N84211 002

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINAMIDE HCL
AP SMITH AND NEPHEW — 100MG/ML — N88530 001 MAR 04, 1985
AP — 500MG/ML — N88531 001 MAR 04, 1985

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINAMIDE HCL
@ SMITH AND NEPHEW — 100MG/ML — N88530 001 MAR 04, 1985
@ — 500MG/ML — N88531 001 MAR 04, 1985
AP STERIS — 100MG/ML — N87079 001
AP — 500MG/ML — N87080 001
@ — 100MG/ML — N87079 001
@ — 500MG/ML — N87080 001

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE
AP SMITH AND NEPHEW — EQ 5MG BASE/ML — N89251 001 DEC 04, 1986
@ — EQ 5MG BASE/ML — N89251 001 DEC 04, 1986
AP STERIS — EQ 5MG BASE/ML — N89606 001 JUL 08, 1987
@ — EQ 5MG BASE/ML — N89606 001 JUL 08, 1987

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMAZINE HCL
AP STERIS — 50MG/ML — N84517 001
— 25MG/ML — N84510 001
@ — 25MG/ML — N84510 001
@ — 50MG/ML — N84517 001
SPARINE
AP + WYETH AYERST — 50MG/ML — N10349 006
+ — 50MG/ML — N10349 006

PROPOFOL

INJECTABLE; INJECTION
DIPRIVAN
AB + ZENECA — 10MG/ML — N19627 002 JUN 11, 1996
+ — 10MG/ML — N19627 002 JUN 11, 1996

PROPOFOL

INJECTABLE; INJECTION
PROPOFOL

AB	GENSIA SICOR PHARMS	10MG/ML	N75102 001	JAN 04, 1999

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
INDERAL

AP	+ WYETH AYERST	1MG/ML	N16419 001	
	+	1MG/ML	N16419 001	

PROPRANOLOL HCL

AP	SMITH AND NEPHEW	1MG/ML	N70137 001	APR 15, 1986
	@	1MG/ML	N70137 001	APR 15, 1986

> ADD > RABEPRAZOLE SODIUM

> ADD > TABLET, DELAYED RELEASE; ORAL
> ADD > ACIPHEX

> ADD >	+ EISAI	20MG	N20973 002	AUG 19, 1999

> ADD >

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

AB	GRANUTEC PHARMS	EQ 150MG BASE	N74488 001	JUL 31, 1997
AB		EQ 300MG BASE	N74488 002	JUL 31, 1997
AB	NOVOPHARM NC	EQ 150MG BASE	N74488 001	JUL 31, 1997
AB		EQ 300MG BASE	N74488 002	JUL 31, 1997
AB	PAR PHARM	EQ 150MG BASE	N75180 001	JAN 28, 1999
AB		EQ 300MG BASE	N75180 002	JAN 28, 1999

> ADD > RAPACURONIUM BROMIDE

> ADD > INJECTABLE; INJECTION
> ADD > RAPLON

> ADD >	ORGANON	100MG/VIAL	N20984 001	AUG 18, 1999
> ADD >				
> ADD >	+	200MG/VIAL	N20984 002	AUG 18, 1999
> ADD >				

RISPERIDONE

TABLET; ORAL
RISPERDAL

	JANSSEN	0.25MG	N20272 008	MAY 10, 1999
	+	0.5MG	N20272 007	JAN 27, 1999

RITONAVIR

CAPSULE; ORAL
NORVIR

	ABBOTT	100MG	N20945 001	JUN 29, 1999

SOLUTION; ORAL
NORVIR

	ABBOTT	80MG/ML	N20659 001	MAR 01, 1996
	+	80MG/ML	N20659 001	MAR 01, 1996

ROFECOXIB

SUSPENSION; ORAL
VIOXX

	MERCK	12.5MG/5ML	N21052 001	MAY 20, 1999
	+	25MG/5ML	N21052 002	MAY 20, 1999

TABLET; ORAL
VIOXX

	MERCK	12.5MG	N21042 001	MAY 20, 1999

ROFECOXIB

TABLET; ORAL
VIOXX
+ MERCK — 25MG — N21042 002 MAY 20, 1999

ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDIA
SMITHKLINE BEECHAM — EQ 2MG BASE — N21071 002 MAY 25, 1999
EQ 4MG BASE — N21071 003 MAY 25, 1999
+ EQ 8MG BASE — N21071 004 MAY 25, 1999

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE
+ HLR — 200MG — N20828 001 NOV 07, 1997
+ ROCHE — 200MG — N20828 001 NOV 07, 1997

SAQUINAVIR MESYLATE

CAPSULE; ORAL
INVIRASE
+ HLR — EQ 200MG BASE — N20628 001 DEC 06, 1995
+ ROCHE — EQ 200MG BASE — N20628 001 DEC 06, 1995

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
ELDEPRYL
@ SOMERSET — 5MG — N19334 001 JUN 05, 1989

SELEGILINE HCL
AB + SOMERSET — 5MG — N19334 001 JUN 05, 1989

SILVER SULFADIAZINE

CREAM; TOPICAL
THERMAZENE
AB KENDALL LP — 1% — N18810 001 DEC 23, 1985
AB SHERWOOD MEDCL — 1% — N18810 001 DEC 23, 1985

SODIUM PHENYLBUTYRATE

POWDER; ORAL
BUPHENYL
+ MEDICIS — 3GM/TEASPOONFUL — N20573 001 APR 30, 1996
+ UCYCLYD — 3GM/TEASPOONFUL — N20573 001 APR 30, 1996

TABLET; ORAL
BUPHENYL
+ MEDICIS — 500MG — N20572 001 MAY 13, 1996
+ UCYCLYD — 500MG — N20572 001 MAY 13, 1996

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
HUMATROPE
BX LILLY — 6MG/VIAL — N19640 005 FEB 04, 1999
+ — 12MG/VIAL — N19640 006 FEB 04, 1999
+ — 24MG/VIAL — N19640 007 FEB 04, 1999

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 10%
AP + FRESENIUS KABI — 10% — N17643 001
AP + PHARMACIA AND UPJOHN — 10% — N17643 001
INTRALIPID 20%
AP + FRESENIUS KABI — 20% — N18449 001
AP + PHARMACIA AND UPJOHN — 20% — N18449 001

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 30%

AP	+	FRESENIUS KABI	30%	N19942 001 DEC 30, 1993
AP	+	PHARMACIA AND UPJOHN	30%	N19942 001 DEC 30, 1993

SPIRONOLACTONE

TABLET; ORAL
ALDACTONE

AB		SEARLE	50MG	N12151 008 DEC 30, 1982
AB	+		100MG	N12151 010 DEC 30, 1983
			50MG	N12151 008 DEC 30, 1982
	+		100MG	N12151 010 DEC 30, 1983

SPIRONOLACTONE

> ADD >	AB	MUTUAL PHARM	50MG	N89424 002 AUG 11, 1999
> ADD >	AB		100MG	N89424 003 AUG 11, 1999
	AB	PUREPAC PHARM	25MG	N87998 001 OCT 14, 1983
	AB		50MG	N40353 001 JUL 29, 1999
	AB		100MG	N40353 002 JUL 29, 1999
		@	25MG	N87998 001 OCT 14, 1983

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SODIUM SULFACETAMIDE

AT	AKORN	10%	N83021 001
AT		15%	N83021 002
AT		30%	N83021 003
	@	10%	N83021 001
	@	15%	N83021 002
	@	30%	N83021 003

SULFACETAMIDE SODIUM

AT	AKORN	10%	N40215 001 MAY 25, 1999

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM

AT	AKORN	30%	N40216 001 MAY 25, 1999

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	STERIS	80MG/ML;16MG/ML	N71556 001 DEC 29, 1987
	@	80MG/ML;16MG/ML	N71556 001 DEC 29, 1987

TACROLIMUS

CAPSULE; ORAL
PROGRAF

+	FUJISAWA HLTHCARE	EQ 1MG BASE	N50708 001 APR 08, 1994
		EQ 0.5MG BASE	N50708 003 AUG 24, 1998
		EQ 1MG BASE	N50708 001 APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
A-N STANNOUS AGGREGATED ALBUMIN

@	NORTH AM CHEMS	N/A	N17916 001
@	SYNCOR PHARMS	N/A	N17916 001

PULMOLITE

BS	CIS	N/A	N17776 001
BS	DUPONT PHARMS	N/A	N17776 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION
MICROLITE

	CIS	N/A	N18263 001 MAR 25, 1983
	DUPONT PHARMS	N/A	N18263 001 MAR 25, 1983

> ADD > TECHNETIUM TC-99M DEPREOTIDE

> ADD > INJECTABLE; INJECTION
> ADD > NEO TECT KIT
> ADD > + DIATIDE N/A N21012 001
> ADD > AUG 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE
CIS N/A N18467 001
MAR 16, 1982
DUPONT PHARMS N/A N18467 001
MAR 16, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

> DLT > INJECTABLE; INJECTION
> DLT > TECHNESCAN HIDA
> DLT > DRAXIMAGE N/A N18489 001
> DLT > OCT 31, 1986
> ADD > @ N/A N18489 001
> ADD > OCT 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
OSTEOLITE
AP CIS N/A N17972 001
AP DUPONT PHARMS N/A N17972 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION
PYROLITE
CIS N/A N17684 001
DUPONT PHARMS N/A N17684 001

> ADD > TEMOZOLOMIDE

> ADD > CAPSULE; ORAL
> ADD > TEMODAR
> ADD > SCHERING 5MG N21029 001
> ADD > AUG 11, 1999

> ADD > TEMOZOLOMIDE

> ADD > CAPSULE; ORAL
> ADD > TEMODAR
> ADD > SCHERING 20MG N21029 002
> ADD > AUG 11, 1999
> ADD > 100MG N21029 003
> ADD > AUG 11, 1999
> ADD > + 250MG N21029 004
> ADD > AUG 11, 1999

TERBUTALINE SULFATE

INJECTABLE; INJECTION
BRETHINE
AP + NOVARTIS 1MG/ML N18571 001
+ 1MG/ML N18571 001
BRICANYL
AP + HOECHST MARION RSSL 1MG/ML N17466 001
@ 1MG/ML N17466 001

TABLET; ORAL
BRETHINE
BP NOVARTIS 2.5MG N17849 001
BP + 5MG N17849 002
2.5MG N17849 001
+ 5MG N17849 002
BRICANYL
BP HOECHST MARION RSSL 2.5MG N17618 001
BP 5MG N17618 002
@ 2.5MG N17618 001
@ 5MG N17618 002

TERIPARATIDE ACETATE

INJECTABLE; INJECTION
PARATHAR
+ RHONE POULENC RORER 200 UNITS/VIAL N19498 001
DEC 23, 1987
@ 200 UNITS/VIAL N19498 001
DEC 23, 1987

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE
STERIS 100MG/ML N85599 001

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE

	@ STERIS	100MG/ML		N85599 001

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL

AB	PUREPAC PHARM	**250MG**		**N60290 001**
AB		**500MG**		**N60290 002**
	@	250MG		N60290 001
	@	500MG		N60290 002
	TETRACYN			
AB	PFIPHARMECS	**250MG**		**N60082 003**
AB		**500MG**		**N60082 004**
	@	250MG		N60082 003
	@	500MG		N60082 004

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEOCLEAR L.A.-130

>DLT>	BC +	CENT PHARMS	130MG		N86569 001
>DLT>					MAY 27, 1982
>ADD>		@ SCHWARZ PHARMA	130MG		N86569 001
>ADD>					MAY 27, 1982

THEOCLEAR L.A.-260

>DLT>	BC +	CENT PHARMS	260MG		N86569 002
>DLT>					MAY 27, 1982
>ADD>		@ SCHWARZ PHARMA	260MG		N86569 002
>ADD>					MAY 27, 1982

INJECTABLE; INJECTION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

	@ B BRAUN	40MG/100ML		N19083 001
				NOV 07, 1984
	@ MCGAW	40MG/100ML		N19083 001
				NOV 07, 1984

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

	@ B BRAUN	80MG/100ML		N19083 002
				NOV 07, 1984
	@ MCGAW	80MG/100ML		N19083 002
				NOV 07, 1984

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

	@ B BRAUN	160MG/100ML		N19083 003
				NOV 07, 1984

THEOPHYLLINE

INJECTABLE; INJECTION
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

	@ MCGAW	160MG/100ML		N19083 003
				NOV 07, 1984

TABLET, EXTENDED RELEASE; ORAL
SUSTAIRE

BC	ROERIG	100MG		N85665 001
BC		300MG		N85665 002
	@	100MG		N85665 001
	@	300MG		N85665 002

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL

AA	ALPHARMA	**EQ 5MG BASE/ML**		**N70969 001**
				OCT 16, 1987
	@	EQ 5MG BASE/ML		N70969 001
				OCT 16, 1987

TIAGABINE HYDROCHLORIDE

TABLET; ORAL
GABITRIL

	+ ABBOTT	2MG		N20646 005
				APR 16, 1999

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID

	@ ROCHE	125MG		N19979 001
				MAR 24, 1993
AB	+ SYNTEX	**250MG**		**N19979 002**
				OCT 31, 1991
	@	125MG		N19979 001
				MAR 24, 1993
	+ SYNTEX USA	250MG		N19979 002
				OCT 31, 1991

TICLOPIDINE HCL

>ADD> **AB**	EON	**250MG**		**N75326 001**
>ADD>				AUG 20, 1999

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLOPIDINE HCL

> ADD >	AB	INVAMED	250MG	N75318 001	> ADD >	
				AUG 20, 1999		
> ADD						
> ADD >	AB	PUREPAC PHARM	250MG	N75253 001	> DLT >	
				AUG 20, 1999		
> ADD >				N75149 001	> DLT >	
> ADD >	AB	TEVA	250MG	AUG 20, 1999		
> ADD >	AB	TORPHARM	250MG	N75089 001		
				JUL 01, 1999		

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AB	ALCON	EQ 0.25% BASE	N20963 001	
			OCT 21, 1998	
AB		EQ 0.5% BASE	N20963 002	
			OCT 21, 1998	
AB	FALCON PHARMS	EQ 0.25% BASE	N20963 001	
			OCT 21, 1998	
AB		EQ 0.5% BASE	N20963 002	
			OCT 21, 1998	

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AT	ADV REMEDIES	EQ 0.5% BASE	N74466 001	
			MAR 25, 1997	
AT	AKORN	EQ 0.5% BASE	N74466 001	
			MAR 25, 1997	
AT	ALCON	EQ 0.25% BASE	N74261 001	
			APR 28, 1995	
AT		EQ 0.5% BASE	N74262 001	
			APR 28, 1995	
@	FALCON PHARMS	EQ 0.25% BASE	N74261 001	
			APR 28, 1995	
@		EQ 0.5% BASE	N74262 001	
			APR 28, 1995	

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBREX

AT	+	ALCON	0.3%	N50541 001
AT	+	FALCON PHARMS	0.3%	N50541 001

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
HYCAMTIN

+	SMITHKLINE	EQ 4MG BASE/VIAL	N20671 001	
			MAY 28, 1996	
+	SMITHKLINE BEECHAM	EQ 4MG BASE/VIAL	N20671 001	
			MAY 28, 1996	

TRETINOIN

SOLUTION; TOPICAL
TRETINOIN

AT	MORTON GROVE	0.05%	N75260 001
			JAN 25, 1999

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
ARISTOCORT

AT	FUJISAWA HLTHCARE	0.025%	N83017 003
AT		0.1%	N83016 004
AT		0.5%	N83015 002
AT	LEDERLE	0.025%	N83017 003
AT		0.1%	N83016 004
AT		0.5%	N83015 002

ARISTOCORT A

AT	FUJISAWA HLTHCARE	0.025%	N83017 004
AT		0.025%	N88818 001
			OCT 16, 1984
AT		0.1%	N83016 005
AT		0.1%	N88819 001
			OCT 16, 1984
AT		0.5%	N83015 003
AT		0.5%	N88820 001
			OCT 16, 1984
AT	LEDERLE	0.025%	N83017 004
AT		0.025%	N88818 001
			OCT 16, 1984
AT		0.1%	N83016 005
AT		0.1%	N88819 001
			OCT 16, 1984
AT		0.5%	N83015 003
AT		0.5%	N88820 001
			OCT 16, 1984

GEL; TOPICAL
ARISTOGEL

@	FUJISAWA HLTHCARE	0.1%	N83380 001

TRIAMCINOLONE ACETONIDE

GEL; TOPICAL
ARISTOGEL
@ LEDERLE 0.1% N83380 001

OINTMENT; TOPICAL
ARISTOCORT
AT FUJISAWA HLTHCARE 0.1% N80750 004
AT 0.5% N80745 002
AT LEDERLE 0.1% N80750 004
AT 0.5% N80745 002
ARISTOCORT A
AT FUJISAWA HLTHCARE 0.1% N80750 003
AT + 0.5% N80745 003
@ 0.5% N88781 001
OCT 05, 1984
AT LEDERLE 0.1% N80750 003
AT + 0.5% N80745 003
@ 0.5% N88781 001
OCT 05, 1984

TRIAMCINOLONE DIACETATE

SYRUP; ORAL
ARISTOCORT
FUJISAWA HLTHCARE 2MG/5ML N11960 004
LEDERLE 2MG/5ML N11960 004

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL
AP SMITH AND NEPHEW 100MG/ML N88960 001
APR 04, 1986
@ 100MG/ML N88960 001
APR 04, 1986

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL
SULFA-TRIPLE #2
AB + GLOBAL PHARM 167MG;167MG;167MG N80079 001
@ 167MG;167MG;167MG N80079 001
TRIPLE SULFOID
AB PAL PAK 167MG;167MG;167MG N80094 001

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL
TRIPLE SULFOID
+ PAL PAK 167MG;167MG;167MG N80094 001

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICAMIDE
AT STERIS 0.5% N89171 001
DEC 28, 1990
@ 0.5% N89171 001
DEC 28, 1990

UREA, C-13

POWDER FOR RECONSTITUTION; ORAL
PYLORI-CHEK BREATH TEST
+ ALIMENTERICS 100MG/VIAL N20900 001
FEB 04, 1999

VALRUBICIN

SOLUTION;
VALSTAR PRESERVATIVE FREE
+ ANTHRA 40MG/ML N20892 001
SEP 25, 1998

SOLUTION; INTRAVESICAL
VALSTAR PRESERVATIVE FREE
+ ANTHRA 40MG/ML N20892 001
SEP 25, 1998

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE
AP ESI LEDERLE 10MG/VIAL N75218 001
AUG 23, 1999
AP 20MG/VIAL N75218 002
AUG 23, 1999
AP GENSIA 10MG/VIAL N74688 001
AUG 25, 1999

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

> ADD >	AP	GENSIA	20MG/VIAL	N74688 002	
> ADD				AUG 25, 1999	

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERAPAMIL HCL

AB		MYLAN	120MG	N75138 001
				APR 20, 1999
AB			180MG	N75138 002
				APR 20, 1999
AB			240MG	N75138 003
				APR 20, 1999
		VERELAN		
	*	ELAN	120MG	N19614 001
				MAY 29, 1990
	*		180MG	N19614 003
				JAN 09, 1992
	*		240MG	N19614 002
				MAY 29, 1990
AB	+	ELAN PHARM	120MG	N19614 001
				MAY 29, 1990
AB	+		180MG	N19614 003
				JAN 09, 1992
AB	+		240MG	N19614 002
				MAY 29, 1990

INJECTABLE; INJECTION
VERAPAMIL HCL

AP		SMITH AND NEPHEW	2.5MG/ML	N70696 001	> DLT >
				JUL 31, 1987	> DLT >
	@		2.5MG/ML	N70696 001	> ADD >
				JUL 31, 1987	

TABLET, EXTENDED RELEASE; ORAL
VERAPAMIL HCL

					> DLT >
					> DLT >
					> ADD >
AB		DURAMED	120MG	N75072 001	> ADD >
				MAY 25, 1999	
AB			240MG	N75072 003	
				MAY 25, 1999	> ADD >
					> ADD >
					> ADD >
					> ADD >

WARFARIN SODIUM

TABLET; ORAL
COUMADIN

AB	*	DUPONT MERCK	2MG	N09218 013
AB			2MG	N09218 013
AB			2.5MG	N09218 018
AB	+		2.5MG	N09218 018
AB			5MG	N09218 007
AB	+		5MG	N09218 007
		WARFARIN SODIUM		
AB		TARO	1MG	N40301 002
				JUL 15, 1999
AB			2MG	N40301 003
				JUL 15, 1999
AB			2.5MG	N40301 004
				JUL 15, 1999
AB			3MG	N40301 005
				JUL 15, 1999
AB			4MG	N40301 006
				JUL 15, 1999
AB			5MG	N40301 007
				JUL 15, 1999
AB			6MG	N40301 008
				JUL 15, 1999
AB			7.5MG	N40301 009
				JUL 15, 1999
AB			10MG	N40301 001
				JUL 15, 1999

XYLOSE

POWDER; ORAL
XYLO-PFAN

AA	*	SAVAGE LABS	25GM/BOT	N17605 001
	@		25GM/BOT	N17605 001
		XYLOSE		
AA		LYNE	25GM/BOT	N18856 001
				MAR 26, 1987
	+		25GM/BOT	N18856 001
				MAR 26, 1987

ZALEPLON

CAPSULE; ORAL
SONATA

	WYETH AYERST	5MG	N20859 001
			AUG 13, 1999

>ADD > ZALEPLON

>ADD > CAPSULE; ORAL
>ADD > SONATA
>ADD > + WYETH AYERST 10MG N20859 002
>ADD > AUG 13, 1999

ZANAMIVIR

CAPSULE; INHALATION
RELENZA
+ GLAXO WELLCOME 5MG N21036 001
JUL 26, 1999

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN + G AND W LABS	120MG	N18060 001
	325MG	N18060 003 DEC 18, 1986
+		N18060 002
+	650MG	N18060 001
	120MG	N18060 003
	325MG	DEC 18, 1986
		N18060 002
	650MG	
ACETAMINOPHEN ASCENT PEDS	120MG	N18337 003 SEP 12, 1983
	325MG	N18337 002
	650MG	N18337 001
+ UPSHER SMITH	120MG	N18337 003 SEP 12, 1983
	325MG	N18337 002
	650MG	N18337 001
INFANTS' FEVERALL ASCENT PEDS	80MG	N18337 004 AUG 26, 1992
UPSHER SMITH	80MG	N18337 004 AUG 26, 1992

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONTAC + SMITHKLINE	8MG;75MG	N18099 001
@	8MG;75MG	N18099 001
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE CENT PHARMS	8MG;75MG	N18809 001 MAY 07, 1984
+	8MG;75MG	N18809 001 MAY 07, 1984

TABLET, EXTENDED RELEASE; ORAL

CONTAC NOVARTIS	12MG;75MG	N19613 001 JUN 13, 1986
+	12MG;75MG	N19613 001 JUN 13, 1986
TRIAMINIC-12 + NOVARTIS	12MG;75MG	N18115 001
@	12MG;75MG	N18115 001

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200 + SMITHKLINE BEECHAM	200MG/20ML	N20951 001 JUL 09, 1999

TABLET; ORAL

CIMETIDINE DANBURY PHARMA	200MG	N75425 001 JUL 29, 1999
ZENITH GOLDLINE	200MG	N75345 001 JUN 16, 1999

CLOTRIMAZOLE

CREAM; TOPICAL

LOTRIMIN AF SCHERING PLOUGH	1%	N17619 002 OCT 27, 1989

LOTION; TOPICAL

LOTRIMIN AF SCHERING	1%	N18813 002 OCT 27, 1989

SOLUTION; TOPICAL

LOTRIMIN AF SCHERING PLOUGH	1%	N17613 002 OCT 27, 1989

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

MEDIHALER-EPI + 3M	0.3MG/INH	N10374 003
@	0.3MG/INH	N10374 003

FAMOTIDINE

TABLET; ORAL

PEPCID AC MERCK	10MG	N20902 001 AUG 05, 1999

> ADD >
> ADD >

IBUPROFEN

SUSPENSION; ORAL
IBUPROFEN
ALPHARMA 100MG/5ML N74916 001 APR 30, 1999

TABLET; ORAL
IBUPROFEN
LNK 200MG N75010 001 MAR 01, 1999
200MG N75139 001 MAR 01, 1999
NORTON HN 200MG N71144 001 JAN 20, 1987
200MG N72901 001 DEC 19, 1991
200MG N72903 001 DEC 19, 1991
ZENITH GOLDLINE 200MG N71144 001 JAN 20, 1987
200MG N72901 001 DEC 19, 1991
200MG N72903 001 DEC 19, 1991

JUNIOR STRENGTH IBUPROFEN
PERRIGO 100MG N75367 001 APR 22, 1999

IBUPROFEN POTASSIUM

CAPSULE; ORAL
PROVEL
+ NOVARTIS 200MG N20402 001 APR 20, 1995 >DLT >
+ WHITEHALL ROBINS 200MG N20402 001 APR 20, 1995 >DLT > >ADD > >ADD >

INSULIN ZINC SUSP PURIFIED BEEF

>DLT > >DLT > >DLT > >ADD >
INJECTABLE; INJECTION
LENTE ILETIN II
+ LILLY 100 UNITS/ML N18477 001
@ 100 UNITS/ML N18477 001

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
M-ZOLE 3 COMBINATION PACK
ALPHARMA US PHARM 2%,200MG N74926 001 APR 16, 1999

MICONAZOLE NITRATE COMBINATION PACK
PERRIGO 2%,200MG N75329 001 APR 20, 1999

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE
ALPHARMA US PHARM 100MG N73507 001 NOV 19, 1993
NMC 100MG N73507 001 NOV 19, 1993

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)
PERRIGO 2% N75357 001 JUL 30, 1999

MINOXIDIL (FOR WOMEN)
PERRIGO 2% N75357 002 JUL 30, 1999

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM
GRANUTEC EQ 200MG BASE N74635 001 JAN 13, 1997
NOVOPHARM NC EQ 200MG BASE N74635 001 JAN 13, 1997

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP
+ ELAN PHARM 11MG/24HR N19983 003 DEC 23, 1998
+ 22MG/24HR N19983 004 DEC 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX		
CIRCA	EQ 2MG BASE	N74507 001 MAR 15, 1999
	EQ 4MG BASE	N74707 001 MAR 19, 1999

NONOXYNOL-9

SPONGE; VAGINAL

TODAY		
@ ALLENDALE PHARMS	1GM	N18683 001 APR 01, 1983
@ WHITEHALL ROBINS	1GM	N18683 001 APR 01, 1983

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HCL		
PERRIGO	120MG	N75153 001 FEB 26, 1999

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HCL		
NOVOPHARM	EQ 75MG BASE	N75094 001 JUN 21, 1999
RANBAXY	EQ 75MG BASE	N75132 001
ZANTAC 75		
+ GLAXO WELLCOME	EQ 75MG BASE	N20520 001 DEC 19, 1995
+ WARNER LAMBERT	EQ 75MG BASE	N20520 001 DEC 19, 1995

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL		
+ NOVARTIS	1%	N20980 001 MAR 09, 1999

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 8 AUG '99

NO AUGUST 1999 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
August 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
111Indium pentetreotide TN= SomatoTher	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation 1600 Canal St. 10th Floor New Orleans, LA 70112 DD=06/10/1999
166Ho-DOTMP TN=	Treatment of multiple myeloma.	NeoRx Corporation 410 W. Harrison Seattle, WA 98119 DD=02/10/1999
6-hydroxymethylacylfulvene TN=	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	MGI Pharma, Inc. Suite 300E, Opus Center 9900 Bren Road East Minnetonka, MN 55343 DD=04/06/1999
6-hydroxymethylacylfulvene TN=	Treatment of ovarian cancer.	MGI Pharma, Inc. 9900 Bren Road East Suite 300E, Opus Center Minnetonka, MN 55343 DD=07/06/1999
6-hydroxymethylacylfulvene TN=	Treatment of renal cell carcinoma.	MGI Pharma, Inc. 9900 Bren Road East Suite 300 E, Opus Center Minnetonka, MN 55343 DD=07/27/1999

Orphan Product Designations and Approvals List
August 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Alitretinoin TN= Panretin	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Sciençe Center Drive San Diego, CA 92121 DD=03/24/1998 MA=02/02/1999
Amifostine TN= Ethyol	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998 MA=06/24/1999
Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized TN= Humate-P	Treatment and prevention of bleeding in hemophilia A (classical hemophilia) in adult patients; and treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate in adult and pediatric patients.	Centeon Pharma GmbH Emil-von-Behring-Strasse 76 35041 Marburg Germany, DD=10/16/1992 MA=04/01/1999
Artesunate TN=	Treatment of malaria.	World Health Organisation Special Programme for Research and Training in Tropical Diseases Via Appia Geneva 27, Switzerland, DD=07/19/1999

Orphan Product Designations and Approvals List
August 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Atovaquone TN= Mepron	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development 5 Moore Drive PO Box 13398 Research Triangle Park, NC 27709 DD=08/14/1991 MA=01/05/1999
Autologous DNP-conjugated tumor vaccine TN= M-Vax	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc. 4520 Main St. Suite 930 Kansas City, MO 64111 DD=02/23/1999
Beraprost TN=	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	United Therapeutics Corporation 68 T.W. Alexander Drive, PO Box 14186 Research Triangle Park, NC 27709 DD=04/29/1999
Bexarotene TN= Targretin	Treatment of cutaneous T-cell lymphoma.	Ligand Pharmaceuticals, Inc. 10275 Science Center Dr. San Diego, CA 92121 DD=06/18/1999
Bleomycin TN= Blenoxane	Treatment of pancreatic cancer.	Genetronics, Inc. 11199 Sorrento Valley Rd. San Diego, CA 92121 DD=02/09/1999

Orphan Product Designations and Approvals List
August 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Busulfan TN= Busulfex	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=07/28/1994 MA=02/04/1999
CT-2584 mesylate TN=	Treatment of adult soft tissue sarcoma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Suite 400 Seattle, WA 98119 DD=04/16/1999
CT-2584 mesylate TN=	Treatment of malignant mesothelioma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Seattle, WA 98119 DD=04/16/1999
Coagulation factor VIIa (recombinant) TN= NovoSeven	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk Pharmaceuticals, Inc. 100 Overlook Center Suite 200 Princeton, NJ 08540 DD=06/06/1988 MA=03/25/1999
Cytarabine liposomal TN= DepoCyt	Treatment of neoplastic meningitis.	DepoTech Corporation 10450 Science Center Drive San Diego, CA 92121 DD=06/02/1993 MA=04/01/1999
Decitabine TN=	Treatment of myelodysplastic syndromes.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem, The Netherlands DD=03/08/1999

Orphan Product Designations and Approvals List
August 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Decitabine TN=	Treatment of chronic myelogenous leukemia.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem, The Netherlands DD=03/08/1999
Denileukin diftitox TN= Ontak	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	Seragen, Inc. 97 South Street Hopkinton, MA 01748 DD=08/21/1996 MA=02/05/1999
Doxorubicin liposome TN= Doxil	Treatment of ovarian cancer.	Alza Corporation 1550 Plymouth St. PO Box 7210 Mountain View, CA 94039 DD=11/04/1998 MA=06/28/1999
Epoprostenol TN= Flolan	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	Glaxo Wellcome Inc. Five Moore Dr. PO Box 13398 Research Triangle Park, NC 27709 DD=03/22/1999
Etanercept TN= Enbrel	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=10/27/1998 MA=05/27/1999

Orphan Product Designations and Approvals List
August 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Etanercept TN= Enbrel	Treatment of Wegener's granulomatosis.	Stone, MD, MPH, John H. Johns Hopkins Vasculitis Center, Division of Rheumatology 1830 East Monument St., Suite 7500 Baltimore, MD 21205 DD=04/06/1999
Fluoxetine TN= Prozac	Treatment of autism.	Hollander, MD, Eric Mt. Sinai School of Medicine, Dept. of Psychiatry Box 1230, One Gustave L. Levy Place New York, NY 10029 DD=04/30/1999
Guanfacine TN= Tenex	Treatment of fragile X syndrome.	Watson Laboratories, Inc. 311 Bonnie Circle PO Box 1900 Corona, CA 91718 DD=08/05/1999
Humanized MAb (IDEC-131) to CD40L TN=	Treatment of systemic lupus erythematosus.	Idec Pharmaceuticals Corporation 3030 Callan Rd. San Diego, CA 92121 DD=02/09/1999
Interferon beta-1a (recombinant human) TN= Avonex	Treatment of pulmonary fibrosis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=01/07/1999

Orphan Product Designations and Approvals List
August 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B) TN= 131IchTNT-1	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Techniclone Corporation 14282 Franklin Ave. Tustin, CA 92780 DD=02/12/1999
Japanese encephalitis vaccine (live, attenuated) TN=	Prevention of Japanese encephalitis.	Boran Pharmaceuticals 3F, Koryo Academytel, 437-3 Ahyun-Dong, Mapo-Gu, Seoul 121-010 South Korea, DD=05/19/1999
L-5-hydroxytryptophan TN=	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc. 311 Bonnie Circle P.O. Box 1900 Corona, CA 91718 DD=01/20/1999
Lactic acid TN= Aphthaid	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc. SUNY Farmingdale Conklin Hall Farmingdale, NY 11735 DD=06/29/1999
Lidocaine patch 5% TN= Lidoderm Patch	For relief of allodynia (painful hypersensitivity), and chronic pain in post-herpetic neuralgia.	Hind Health Care, Inc. 3707 Williams Rd., Suite 101 San Jose, CA 95117 DD=10/24/1995 MA=03/19/1999

Orphan Product Designations and Approvals List
August 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II) TN=	Treatment of malignant mesothelioma.	Aronex Pharmaceuticals, Inc. 8707 Technolgoy Forest Place The Woodlands, TX 77381 DD=09/01/1999
Lisofylline TN=	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc. 201 Elliot Ave. W., Suite 400 Seattle, WA 98119 DD=06/10/1999
Marijuana TN=	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc. 3 Francis St. Belmont, MA 02478 DD=05/25/1999
Mitoxantrone TN= Novantrone	Treatment of secondary-progressive multiple sclerosis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=08/13/1999
Mitoxantrone TN= Novantrone	Treatment of progressive-relapsing multiple sclerosis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=08/13/1999
Murine MAb to polymorphic epithelial mucin, human milk fat globule 1 TN= Theragyn	Adjuvant treatment of ovarian cancer.	Antisoma West Africa House Hanger Lane London W5 3QR, UK DD=03/22/1999

Orphan Product Designations and Approvals List
August 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
N-acetylgalactosamine-4-sulfatase, recombinant human TN=	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc. 11 Pimental Court Novato, CA 94949 DD=02/17/1999
Parovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine TN= MEDI-491	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg, MD 20878 DD=05/07/1999
Pegylated arginine deiminase TN= Hepacid	Treatment of hepatocellular carcinoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=03/26/1999
Pegylated arginine deiminase TN= Melanocid	Treatment of invasive malignant melanoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=04/12/1999
Recombinant human C1-esterase inhibitor TN=	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel, Belgium DD=02/23/1999
Recombinant human C1-esterase inhibitor TN=	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel, Belgium DD=02/23/1999

Orphan Product Designations and Approvals List
August 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant human insulin-like growth factor-I/insulin -like growth factor binding protein-3 TN=	Treatment of major burns that require hospitalization.	Celtrix Pharmaceuticals, Inc. 3055 Patrick Henry Dr. Santa Clara, CA 95054 DD=06/15/1999
Recombinant human nerve growth factor TN=	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=04/16/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of solid organ transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Rifalazil TN=	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=04/13/1999
SCH 58500 TN=	Treatment of primary ovarian cancer.	Schering Corporation 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=04/12/1999

Orphan Product Designations and Approvals List
August 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Sodium 1,3-propanedisulfonate TN=	Treatment of secondary amyloidosis.	Neurochem, Inc. 7220 Frederick Banting, Suite 100 Saint-Laurent, Quebec Canada H4S 2A1, DD=04/06/1999
Sodium dichloroacetate TN= Ceresine	Treatment of severe head injury.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=06/14/1999
Somatropin [rDNA] TN= Genotropin	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn 7000 Portage Rd. 0633-298-113 Kalamazoo, MI 49001 DD=07/06/1999
Synthetic human secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 1550 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic human secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic human secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic porcine secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999

Orphan Product Designations and Approvals List
August 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Synthetic porcine secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Temozolomide TN= Temodar	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=10/05/1998 MA=08/11/1999
Thalidomide TN= Thalomid	Treatment of Crohn's disease.	Celgene Corporation 7 Powder Horn Dr. Warren, NJ 07059 DD=04/06/1999
Tobramycin TN= Tobi	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=06/18/1999
Transgenic human alpha 1 antitrypsin TN=	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K. DD=05/19/1999

Orphan Product Designations and Approvals List
August 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembryonic antigen IgG antibody TN= Cea-Cide	Treatment of ovarian carcinoma.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=08/03/1999

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO AUGUST 1999 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 19TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

NP* NEW PRODUCT (MINT FLAVORED)

REFERENCES

NEW DOSING SCHEDULE

D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS

NEW INDICATION

I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C

I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER

I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN

I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN

I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)

I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)

I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY

I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION

I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES FOUR AND ABOVE

I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)

I-261 TREATMENT OF SOCIAL ANXIETY DISORDER

I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12

I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY

I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION

I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER

I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES

I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER-FOR CORTICOSTEROID-RESPONSIVE DERMATOSES

I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN

REFERENCES

MISCELLANEOUS EXCLUSIVITY CODES

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION

PATENT USE CODE

U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECITON IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN.
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN.
U-265	USE AS A LAXATIVE
U-266	OSTEOARTHRITIS
U-267	METHOD FOR PREVENTING HEARTBURN
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD FOR IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY, TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020482 004	ACARBOSE;PRECOSE				I-252	SEP 29, 2001
						I-253	SEP 29, 2001
	020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010	U-134		
			RE34440	MAR 31, 2010	U-275		
	020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010	U-134		
			RE34440	MAY 31, 2010	U-275		
>ADD>	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282		
>ADD>			5763454	JUN 15, 2015	U-282		
>ADD>	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282		
>ADD>			5763454	JUN 15, 2015	U-282		
	020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA				I-262	JUN 02, 2002
	019621 001	ALBUTEROL SULFATE;VENTOLIN	4594359	JUN 10, 2003			
	020886 001	ALITRETINOIN;PANRETIN				ODE	FEB 02, 2006
						NCE	FEB 02, 2004
	020221 001	AMIFOSTINE;ETHYOL				ODE	JUN 24, 2006
>ADD>	020508 001	AMMONIUM LACTATE;LAC-HYDRIN				PED	FEB 29, 2000
	021007 001	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021007 002	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021039 001	AMPRENAVIR;AGENERASE	5585397	DEC 17, 2013		NCE	APR 15, 2004
	020500 001	ATOVAQUONE;MEPRON				ODE	JAN 05, 2006
						I-255	JAN 05, 2002
	020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			
	020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			
	020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
			5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
>ADD>	020793 001	CAFFEINE;CAFCIT				NE	SEP 21, 2002
	020313 002	CALCITONIN, SALMON;MIACALCIN	5759565	JUN 02, 2015			
	020896 001	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271		
			4966891	NOV 08, 2008	U-272		
	020896 002	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271		
			4966891	NOV 08, 2008	U-272		
	020712 001	CARBAMAZEPINE;CARBATROL	5912013	JUN 15, 2016	U-277		
	020712 002	CARBAMAZEPINE;CARBATROL	5912013	JUN 15, 2016	U-277		
	020998 001	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			
	020998 002	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			
	020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NS	MAY 24, 2002
			5177080	NOV 26, 2011			
	020638 001	CIDOFOVIR;VISTIDE	5142051	JUN 26, 2010			
>ADD>	020863 001	CILOSTAZOL;PLETAL	4277479	AUG 29, 2000		NCE	JAN 15, 2004
>ADD>	020863 002	CILOSTAZOL;PLETAL	4277479	AUG 29, 2000		NCE	JAN 15, 2004
	019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
			5286754	FEB 15, 2011			
	020767 001	CISAPRIDE MONOHYDRATE;PROPULSID QUICKSOLV	5648093	JUL 15, 2014			
	021041 001	CYTARABINE;DEPOCYT				ODE	APR 01, 2006
						NP	APR 01, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020287 001	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 003	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 004	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	017922 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 003	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	074752 001	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 19, 1999
	074752 003	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 19, 1999
	074752 004	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 19, 1999
	020449 001	DOCETAXEL;TAXOTERE	4814470	MAY 14, 2010			
			5438072	NOV 22, 2013			
			5698582	JUL 03, 2012			
			5714512	JUL 03, 2012			
	020862 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-278	NCE	JUN 09, 2004
			5707980	FEB 11, 2117	U-278		
						ODE	JUN 28, 2006
	050718 001	DOXORUBICIN HYDROCHLORIDE;DOXIL	5811423	AUG 07, 2012	U-256		
	020972 001	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
	020972 002	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256		
			5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
	020972 003	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
			5811423	AUG 07, 2012	U-256		
	020375 001	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 002	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 003	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 004	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
	020908 001	ESTRADIOL;VAGIFEM				NP	MAR 26, 2002
	020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NP	MAR 24, 2002
	020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NP	MAR 24, 2002
>ADD>	020527 001	ESTROGENS, CONJUGATED;PREMPRO 14/14	RE36247	MAY 02, 2006			
>ADD>	020527 003	ESTROGENS, CONJUGATED;PREMPRO 14/14	RE36247	MAY 02, 2006			
			4826831	MAY 02, 2006			
			5547948	JAN 17, 2015			
	020363 001	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
	020363 003	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
	020325 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-267		
>ADD>	020801 001	FAMOTIDINE;PEPCID AC	5677794	MAY 02, 2015	U-279		
>ADD>			5075114	DEC 24, 2008			
			5854267	DEC 29, 2015	U-267		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019304 002	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
	020747 001	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 002	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 003	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 004	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 005	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 006	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020955 001	FERRIC SODIUM GLUCONATE;FERRLECIT				NCE	FEB 18, 2004
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5855912	FEB 28, 2015			
			5738872	FEB 28, 2015			
	020788 001	FINASTERIDE;PROPECIA	5571817	NOV 05, 2013	U-259		
			5886184	NOV 19, 2012			
>ADD>	020180 001	FINASTERIDE;PROSCAR	5942519	OCT 23, 2018	U-280		
			4760071	JUN 19, 2006	U-262		
			5886184	NOV 19, 2012			
			4377584	MAR 22, 2000	U-261		
	019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-265	AUG 18, 2002
>ADD>	020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
					U-154		
>ADD>	020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
>ADD>			4626549	DEC 02, 2003	U-154		
			4314081	FEB 02, 2001			
>ADD>	020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
>ADD>			4626549	DEC 02, 2003	U-154		
			4314081	FEB 02, 2001			
	019958 001	FLUTICASONE PROPIONATE;CUTIVATE				I-267	JUN 17, 2002
	020121 001	FLUTICASONE PROPIONATE;FLONASE				I-258	DEC 11, 2001
	020882 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		
	020882 002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		
	021057 001	GANIRELIX ACETATE;ANTAGON	4801577	FEB 05, 2007		NCE	JUL 29, 2004
			5767082	JUN 16, 2015			
>ADD>	020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010			
>ADD>	020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010			
>ADD>	020496 001	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
>ADD>	020496 002	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
>ADD>	020496 003	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
	020305 001	GRANISETRON HYDROCHLORIDE;KYTRIL				I-264	JUL 27, 2002
	020305 002	GRANISETRON HYDROCHLORIDE;KYTRIL				I-264	JUL 27, 2002
	020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
	020491 001	IBUTILIDE FUMARATE;CORVERT				D-50	MAY 13, 2002
>ADD>	021028 001	INSULIN HUMAN;VELOSULIN BR				NP	JUL 19, 2002
	020083 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020657 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020966 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
			4267179	JUN 23, 2000			
	021066 001	KETOTIFEN FUMARATE;ZADITOR				NCE	JUL 02, 2004
	020564 001	LAMIVUDINE;EPIVIR	5905082	MAY 18, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
>ADD>			5532246	JUL 02, 2013	U-250		
>ADD>			5905082	MAY 18, 2016			
>ADD>	021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
>ADD>			5532246	JUL 02, 2013	U-250		
	020764 001	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 002	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 003	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
>ADD>	020406 001	LANSOPRAZOLE;PREVACID				M-1	JUL 06, 2002
>ADD>	020406 002	LANSOPRAZOLE;PREVACID				M-1	JUL 06, 2002
	020597 001	LATANOPROST;XALATAN	5296504	MAR 22, 2011	U-260		
			5422368	MAR 22, 2011	U-260		
			4599353	JUL 28, 2006	U-260		
	020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	4652441	NOV 01, 2004			
	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX				NP	MAR 25, 2002
	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX				NP	MAR 25, 2002
	020997 001	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
	020997 002	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
	020997 003	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276		
	021045 001	LEVONORGESTREL;PLAN B				NP	JUL 28, 2002
	019941 001	LIDOCAINE;EMLA				I-260	MAR 11, 2002
	020612 001	LIDOCAINE;LIDODERM				ODE	MAR 19, 2006
	019777 006	LISINOPRIL;ZESTRIL	4374829	DEC 30, 2001			
	019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	020969 001	METHOXSALEN;UVADEX	4845075	APR 11, 2009		NP	FEB 25, 2002
			5036102	JUL 30, 2008	U-273		
			4999375	MAR 12, 2008			
	020968 001	MICONAZOLE NITRATE;MONISTAT DUAL- PAK	5514698	MAR 21, 2014		NP	JUN 30, 2002
	020682 001	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020682 002	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020682 003	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020717 001	MODAFINIL;PROVIGIL	4177290	MAR 09, 1999			
			5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		
	020717 002	MODAFINIL;PROVIGIL	4177290	MAR 09, 1999			
			5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		
	018612 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020066 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020385 001	NICOTINE;NICOTROL	5656255	AUG 12, 2014			
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			
	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
			5922682	JUL 13, 2016			
	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	ODE	NOV 25, 2005
			4395403	NOV 21, 2002	U-269		
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			
>ADD>	020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN				I-269	AUG 27, 2002
>ADD>	020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN				I-269	AUG 27, 2002
	020766 001	ORLISTAT;XENICAL				NCE	APR 23, 2004
	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	4783337	SEP 16, 2003		NP	DEC 16, 2001
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			5840754	MAY 22, 2015			
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
			5912268	MAY 22, 2015			
	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	5840754	MAY 22, 2015		NP	DEC 16, 2001
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
			5912268	MAY 22, 2015			
	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	5912268	MAY 22, 2015		NP	DEC 16, 2001
			4612008	SEP 16, 2003			
			4519801	JUL 12, 2002			
			5840754	MAY 22, 2015			
			5674895	MAY 22, 2015			
			5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
	020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			
	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			
>ADD>	021079 001	PEMIROLAST POTASSIUM;ALAMAST	5034230	DEC 23, 2008	U-184	PED	MAR 24, 2005
>ADD>			5034230*PED	JUN 23, 2009	U-184	NCE	SEP 24, 2004
	021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
			4687777	JAN 17, 2006			
	021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
			4687777	JAN 17, 2006			
	021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
			4687777	JAN 17, 2006			
	020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	5710183	JUL 14, 2015	U-265	NP	FEB 18, 2002
	019627 002	PROPOFOL;DIPRIVAN	5714520	MAR 22, 2015			
			5714520*PED	SEP 22, 2015			
			5731355	MAR 22, 2015	U-217		
			5731355*PED	SEP 22, 2015	U-217		
			5731356	MAR 22, 2015	U-218		
			5731356*PED	SEP 22, 2015	U-218		
			5908869	MAR 22, 2015	U-270		
			5908869*PED	SEP 22, 2015	U-270		
	075102 001	PROPOFOL;PROPOFOL				PC	OCT 16, 1999
	020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
	020973 002	RABEPRAZOLE SODIUM;ACIPHEX				NCE	AUG 19, 2004
	075094 001	RANITIDINE HYDROCHLORIDE;RANITIDINE HCL				PC	JAN 13, 2000
>ADD>	020984 001	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
>ADD>	020984 002	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
	020903 001	RIBAVIRIN;REBETOL	5914128	DEC 22, 2017			
	020272 007	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37	OCT 17, 2000
			4804663	DEC 29, 2007	U-90		
	020272 008	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	D-37	OCT 17, 2000
			5158952	OCT 27, 2009	U-90		
>ADD>	020680 001	RITONAVIR;NORVIR	5948436	SEP 13, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5457895	OCT 01, 2013			
	020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5457895	OCT 01, 2013			
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
>ADD>	019640 005	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
>ADD>						ODE	DEC 30, 2003
>ADD>	019640 006	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
>ADD>						ODE	DEC 30, 2003
>ADD>	019640 007	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
>ADD>						ODE	DEC 30, 2003
	021012 001	TECHNETIUM TC-99M DEPREOTIDE;NEO TECT KIT				NCE	AUG 03, 2004
	021029 001	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 002	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 003	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 004	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	074823 001	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 08, 2000
	074823 002	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 08, 2000
	074823 003	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 08, 2000
	074823 004	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 08, 2000
>ADD>	020539 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-281		
>ADD>	020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL				NCE	DEC 30, 1999
	020980 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-73	NCE	DEC 30, 1999
			4755534	DEC 30, 2006	U-73		
>ADD>	020846 001	TERBINAFINE;LAMISIL				NP	APR 29, 2001
						NCE	DEC 30, 1999
	019762 001	TESTOSTERONE;TESTODERM	5840327	AUG 15, 2016			
	019762 002	TESTOSTERONE;TESTODERM	5840327	AUG 15, 2016			
	020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
			5354760	MAR 24, 2012			
	020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230		
			5880136	SEP 27, 2010	U-254		
	020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U-230		
			5880136	SEP 27, 2010	U-254		
	020505 001	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
	020505 002	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
	020505 003	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020505 004	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
	020505 005	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
	020505 006	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				I-266	JUL 23, 2002
	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				I-266	JUL 23, 2002
	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				I-266	JUL 23, 2002
	020671 001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN				I-256	NOV 30, 2001
>ADD>	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	5164402	NOV 17, 2009	U-282		
>ADD>			5763454	JUN 15, 2015	U-282		
>ADD>	020759 002	TROVAFLOXACIN MESYLATE;TROVAN	5164402	NOV 17, 2009	U-282		
>ADD>			5763454	JUN 15, 2015	U-282		
>ADD>	020900 001	UREA, C-13;PYLORI-CHEK BREATH TEST				NCE	SEP 17, 2001
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	019614 004	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007			
	020943 001	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020943 002	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020943 003	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
>ADD>	020547 001	ZAFIRLUKAST;ACCOLATE				I-268	SEP 17, 2002
	020859 001	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
	020859 002	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
	021036 001	ZANAMIVIR;RELENZA	D379506	MAY 27, 2011		NCE	JUL 26, 2004
			4778054	OCT 18, 2005			
			4811731	JUL 29, 2006			
			5035237	JUL 30, 2008			
			5360817	NOV 01, 2011			
			5648379	JUL 15, 2014	U-274		
			4627432	DEC 09, 2003			